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Performing Agreed-Upon 
Procedures Engagements 
That Address Internal 
Control Over Derivative 
Transactions as Required 
by the N ew  York State 
Insurance Law
Issued by the
Auditing Standards Board
NOTE
This Statement of Position represents the recommenda­
tions of the AICPA’s Reporting on Internal Control Over 
Derivative Transactions at Insurance Entities Task Force 
regarding the application of Statements on Standards for 
Attestation Engagements to agreed-upon procedures en­
gagements performed to comply with the requirements of 
Section 1410 (b )(5 ) of the New York State Insurance Law, 
as amended (the Law), which addresses the assessment of 
internal control over derivative transactions as defined in 
Section 1401(a) of the Law, and Section 178.6(b) of Regu­
lation No. 163. The Auditing Standards Board has found 
the recommendations in this Statement of Position to be 
consistent with existing standards covered by Rule 202 of 
the AICPA Code of Professional Conduct. AICPA members 
should be aware that they may have to justify departures 
from the recommendations in this Statement of Position if 
the quality of their work is questioned.
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Performing  A greed-U p o n  Procedures 
En g a g em en ts  T h a t A ddress Internal Co n tr o l  
O ver D erivative T r a n sa ctio n s  as  Required by 
the N ew  Y o r k  State Insurance  La w
Introduction and Background
1. The New York State Insurance Department (the Depart­
ment) has issued regulations to implement the New York 
Derivative Law (the Law) which amends Article 14 of the 
State of New York Insurance Law, effective July 1, 1999. 
The Law establishes certain requirements for domestic life 
insurers, domestic property and casualty insurers, domes­
tic reciprocal insurers, domestic mortgage guaranty insur­
ers, domestic cooperative property and casualty insurance 
corporations, and domestic financial guaranty insurers. 
Foreign insurers engaging in derivative transactions and 
derivative instruments are subject to and required to com­
ply with all of the provisions of the Law. However, a foreign 
insurer may enter into other derivative transactions pro­
vided the insurer meets certain conditions of its domestic 
state law. In this document, an insurer covered by the Law 
is referred to as an insurance company.
2. The requirements of the Law include the following:
• Approval by the board of directors, or a similar body, 
of derivative transactions
• Submission of a derivative use plan (the DUP) to the 
Department
• Assessment by an independent certified public ac­
countant (CPA) of the insurance company’s internal 
control over derivative transactions
3. In addition to the Law, the Department also has established 
Regulation No. 163, “Derivative Transactions” (11 NYCRR 
178) (the Regulation), which provides guidance in imple­
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menting the Law. Section 178.6(b) of Regulation No. 163 
states the following.
As set forth in section 1410 (b )(5 ) of the Insurance Law, 
an insurer engaging in derivative transactions shall be 
required to include, as part of the evaluation of account­
ing procedures and internal controls required to be filed 
pursuant to section 307 of the Insurance Law, a state­
ment describing the assessment by the independent cer­
tified public accountant of the internal controls relative 
to derivative transactions. The purpose of this part of the 
evaluation is to assess the adequacy of the internal con­
trols relative to the derivative transactions. Such an as­
sessment shall be made whether or not the derivative 
transactions are material in relation to the insurer’s fi­
nancial statements and shall report all material deficien­
cies in internal control relative to derivative 
transactions, whether or not such deficiencies would 
lead to an otherwise “reportable condition,” as that term 
is used in auditing standards adhered to by certified pub­
lic accountants. The statement describing the assess­
ment need not be set forth in a separate report.
4. The Department has proposed that the Regulation be 
amended to provide that an assessment in the form of an 
agreed-upon procedures engagement or other attestation 
engagement, as those terms are used in standards adhered 
to by CPAs, may be used to meet the requirement for an 
assessment of internal control over derivative transactions. 
This proposed amendment to the Regulation has not been 
promulgated at the date of this Statement of Position 
(SOP). However, in a letter dated April 27, 2001, the De­
partment stated the following:
This letter confirms that in determining compliance with 
Section 1410(b)(5 ) of the Insurance Law, the Depart­
ment acknowledges that an agreed-upon procedures en­
gagement, including an engagement performed using the 
procedures in the proposed SOP ( “Performing Agreed- 
Upon Procedures Engagements that Address Internal 
Control Over Derivative Transactions as Required by the 
New York State Insurance Law”), can be used to satisfy 
the statutory requirement.
D
5. The DUP was due to be filed by applicable insurance com­
panies by January 1, 2000. The first independent CPA’s re­
port is due on June 1, 2001. The Law expires on June 30, 
2003; however, the State of New York may extend the expi­
ration date.
6. As previously stated, the letter from the Department indi­
cates that an agreed-upon procedures engagement or other 
attestation engagement may be used to satisfy the require­
ments of the Law. However, this SOP only describes an 
agreed-upon procedures engagement. It does not address 
any other attestation engagements that might be per­
formed, such as an examination-level attestation engage­
ment. For guidance on performing such other attestation 
engagements, see “Attest Engagements,” in Statement on 
Standards for Attestation Engagements (SSAE) No. 10, At­
testation Standards: Revision and Codification (AICPA, 
Professional Standards, vol. 1, AT sec 101).
Applicability
7. This SOP was developed to provide practitioners with guid­
ance on performing agreed-upon procedures engagements 
that address an insurance company’s internal control over 
derivative transactions to meet the requirements of the 
Law. Practitioners should note that the engagement de­
scribed in this SOP is designed only to satisfy the require­
ments of the Law. The procedures, as set forth in this SOP, 
are not necessarily appropriate for use in any other en­
gagement.
8. Although the Department has indicated that an agreed- 
upon procedures engagement pursuant to this SOP can be 
used to satisfy the requirements for an assessment of inter­
nal control over derivative transactions, the Department 
has not agreed to the sufficiency of the procedures in­
cluded in this SOP for their purposes.
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The Law
Definition of a Derivative
9. Article 14 of the Law defines a derivative instrument as in­
cluding caps, collars, floors, forwards, futures, options, 
swaps, swaptions, and warrants.
10. The following definitions are included in the Law and are 
applicable when performing the agreed-upon procedures 
engagement described in this SOP.
Cap— An agreement obligating the seller to make pay­
ments to the buyer with each payment based on the 
amount by which a reference price or level or the perfor­
mance or value of one or more underlying interests ex­
ceeds a predetermined number, sometimes called the 
strike rate or strike price.
Collar— An agreement to receive payments as the buyer 
of an option, cap, or floor and to make payments as the 
seller of a different option, cap, or floor.
Floor— An agreement obligating the seller to make pay­
ments to the buyer in which each payment is based on 
the amount by which a predetermined number, some­
times called the floor rate or price, exceeds a reference 
price, level, performance, or value of one or more under­
lying interests.
Forward— An agreement (other than a future) to make 
or take delivery in the future of one or more underlying 
interests, or effect a cash settlement, based on the actual 
or expected price, level, performance, or value of such 
underlying interests, but shall not mean or include spot 
transactions effected within customary settlement peri­
ods, when-issued purchases, or other similar cash mar­
ket transactions.
Future— An agreement traded on a futures exchange, to 
make or take delivery of, or effect a cash settlement 
based on the actual or expected price, level, perfor­
mance, or value of one or more underlying interests.
8 
Option—An agreement giving the buyer the right to buy 
or receive (a call option), sell or deliver (a put option), 
enter into, extend or terminate, or effect a cash settle­
ment based on the actual or expected price, spread, 
level, performance, or value of one or more underlying 
interests.
Swap—An agreement to exchange or to net payments at 
one or more times based on the actual or expected price, 
yield, level, performance, or value of one or more under­
lying interests.
Swaption— An option to purchase or sell a swap at a 
given price and time or at a series of prices and times. A 
swaption does not mean a swap with an embedded op­
tion.
Warrant—An instrument that gives the holder the right 
to purchase or sell the underlying interest at a given 
price and time or at a series of prices and times outlined 
in the warrant agreement.
Article 14 of the Law permits an insurance company to 
enter into replication transactions provided that certain 
conditions set forth in the Law are met. A replication trans­
action is defined in the Law as follows.
A  derivative transaction or combination of derivative 
transactions effected either separately or in conjunction 
with cash market investments included in the insurer’s 
investment portfolio in order to replicate the investment 
characteristic of another authorized transaction, invest­
ment or instrument and/or operate as a substitute for 
cash market transactions. A  derivative transaction en­
tered into by the insurer as a hedging transaction or in­
come generation transaction authorized pursuant to this 
section [of the Law] shall not be considered a replication 
transaction.
9
Derivative Use Plan
12. An insurance company entering into derivative transac­
tions must file a DUP with the Department. The DUP gen­
erally should include the following items.1
• A  certified copy of the authorization by the insurer’s 
board of directors, or other similar body, to file the 
DUP, which should include authorization of deriva­
tive transactions and an assurance that individuals 
responsible for derivative transactions, processes, 
and controls have the necessary experience and 
knowledge
• A section on management oversight standards in­
cluding a discussion of the following:
-  Limits on identified risks
-  Controls over the nature and amount of identified 
risks
-  Processes for identifying such risks
-  Processes for documenting, monitoring, and re­
porting risk exposure
-  Internal audit and review processes that ensure 
integrity of the overall risk management process
-  Quarterly reporting to the board of directors
-  The establishment of risk tolerance levels
-  Management’s measurement and monitoring 
against those levels
• A  section on internal control and reporting including 
a discussion of the following:
-  The existence of controls over the valuation and 
effectiveness of derivative instruments
-  Credit risk management
-  The adequacy of professional personnel
-  Technical expertise and systems
-  Management reporting
1. Reference should be made to the Law  and the Regulation for specific details and exact 
requirements.
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-  The review and legal enforceability of derivative 
contracts between parties
• A section on documentation and reporting require­
ments which shall for each derivative transaction 
document the following:
-  The purpose of the transaction
-  The assets or liabilities to which the transaction 
relates
-  The specific derivative instrument used
-  For over-the-counter (O T C) transactions, the 
name of the counterparty and counterparty expo­
sure amount
-  For exchange traded transactions, the name of the 
exchange and the name of the firm handling the 
trade
• Written guidelines to be followed in engaging in de­
rivative transactions. The guidelines should include 
or address the following:
-  The type, maturity, and diversification of deriva­
tive instruments
-  The limitation on counterparty exposures, includ­
ing limitations based on credit ratings
-  The limitations on the use of derivatives
-  Asset and liability management practices with re­
spect to derivative transactions
-  The liquidity needs and the insurance company’s 
capital and surplus as it relates to the DUP
-  The policy objectives of management specific 
enough to outline permissible derivative strategies
-  The relationship of the strategies to the insurer’s 
operations
-  How the strategies relate to the insurer’s risk
-  A  requirement that management establish and ex­
ecute management oversight standards as re­
quired by the Law
1
-  A requirement that management establish and ex­
ecute internal control and reporting standards as 
required by the Law
-  A requirement that management establish and ex­
ecute documentation and reporting standards as 
required by the Law
• Guidelines for the insurer’s determination of accept­
able levels of basis risk, credit risk, foreign currency 
risk, interest rate risk, market risk, operational risk, 
and option risk
• A requirement that the board of directors and senior 
management comply with risk oversight functions 
and adhere to laws, rules, regulations, prescribed 
practices, or ethical standards
Related Professional Standards
AT Section 201, "Agreed-Upon Procedures 
Engagements,"  Statement on Standards for 
Attestation Engagements No. 10
13. Agreed-upon procedures engagements performed to meet 
the requirements of the Law are to be performed in accor­
dance with AT Section 201, “Agreed-Upon Procedures En­
gagements,” in SSAE No. 10. As described in AT Section 
201.03, an agreed-upon procedures engagement is one in 
which a practitioner is engaged by a client to issue a report 
of findings based on specific procedures performed on the 
subject matter. Not all of the provisions of AT Section 201 
are discussed herein. Rather, this SOP includes guidance to 
assist practitioners in the application of selected aspects of 
AT Section 201.
14. AT section 201.06 states, in part, that the practitioner may 
perform an agreed-upon procedures engagement provided 
that, “ ...(c) the practitioner and the specified parties agree 
upon the procedures performed or to be performed by the 
practitioner; and (d) the specified parties take responsibil­
ity for the sufficiency of the agreed-upon procedures for 
their purposes.”
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15. As previously stated, the letter from the Department states 
that an agreed-upon procedures engagement may be used 
to meet the requirement for an independent CPA’s assess­
ment of internal control over derivative transactions, and 
acknowledges the use of this SOP in such engagements. Ac­
cordingly, practitioners should not eliminate any of the 
procedures presented in appendix B, “Agreed-Upon Proce­
dures for Testing Internal Control Over Derivative Transac­
tions,” of this SOP or reduce the extent of the tests. The 
Department or the insurance company may request that 
additional procedures be performed and the practitioner 
may agree to perform such procedures. In those circum­
stances, it would be expected that the additional proce­
dures would be performed in the context of a separate 
agreed-upon procedures engagement.
16. As previously noted, the Department has not agreed to the 
sufficiency of the procedures included in this SOP for their 
purposes. Therefore, the Department should not be named 
as a specified party to the agreed-upon procedures report, 
and the use of a practitioner’s agreed-upon procedures re­
port, issued in accordance with this SOP, should be re­
stricted to the board of directors and management of the 
insurance company. Although the Department is not a 
specified party, footnote 15 of AT Section 101, Attest En­
gagements, states the following, in part:
... a regulatory agency as part of its oversight responsi­
bility for an entity may require access to restricted-use 
reports in which they are not named as a specified party.
Statement on Auditing Standards No. 92, Auditing 
Derivative Instruments, Hedging Activities, and  
Investments in Securities
17. Statement on Auditing Standards (SAS) No. 92, Auditing 
Derivative Instruments, Hedging Activities, and Invest­
ments in Securities (AICPA, Professional Standards, vol. 
1, AU sec. sec. 332), provides guidance to auditors in plan­
ning and performing auditing procedures for financial 
statement assertions about derivative instruments, hedging 
activities, and investments in securities in a financial state­
ment audit performed in accordance with generally ac­
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cepted auditing standards. A  practitioner performing the 
agreed-upon procedures engagement described in this SOP 
may find it helpful to consider the guidance in SAS No. 92 
and the related audit guide of the same name supporting 
SAS No. 92. Specifically, the practitioner should consider 
AU Sections 332.5 and 332.6 of SAS No. 92 which describe 
the need for special skill or knowledge to plan and perform 
the auditing procedures presented in SAS No. 92. That 
same skill and knowledge is needed to perform the proce­
dures described in this SOP.
18. The procedures in this SOP are not designed to meet the 
requirements of generally accepted auditing standards for 
an audit of the financial statements of an entity that en­
gages in derivative transactions. In addition, performing 
the audit procedures described in SAS No. 92 would not 
meet the requirements of this SOP.
19. In an audit of financial statements, the auditor may deter­
mine that he or she will not perform procedures related to 
derivative transactions because they are not material to the 
financial statements. There is no requirement to perform 
the procedures described in this SOP when performing an 
audit of financial statements. In contrast, the Law requires 
that an assessment of internal control be performed 
whether or not the derivative transactions are material to 
the insurer’s financial statements. Accordingly, a decision 
not to perform procedures related to derivative transactions 
in an audit of financial statements, because of immaterial­
ity, would not alleviate the requirement to perform the 
agreed-upon procedures engagement described herein.
Procedures to Be Performed
20. The agreed-upon procedures to be performed are directed 
toward tests of controls over derivative transactions that 
occurred during the period covered by the practitioner’s 
report. Any projection of the practitioner’s findings to the 
future is subject to the risk that because of change, the 
controls may no longer be in existence, suitably designed, 
or operating effectively. Also, the potential effectiveness of 
controls over derivative transactions is subject to inherent
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limitations and, accordingly, errors or fraud may occur and 
not be detected.
21. The procedures to be performed in the agreed-upon proce­
dures engagement described in this SOP are presented in 
Appendix B. The procedures have been designed so that 
the findings resulting from the application of the proce­
dures can be recorded in a tabular format. The findings for 
each procedure should be reported as No Exception, Ex­
ception, or N/A (not applicable). If a procedure is not ap­
plicable to a particular insurance company, the procedure 
should be marked N/A rather than deleted from the report.
22. Section 1 of Appendix B of this SOP is applicable to all in­
surance companies that enter into derivative transactions. 
Therefore, the procedures in section 1 are to be performed 
in all engagements performed in accordance with this SOP. 
Sections 2 through 10 of Appendix B of this SOP each ad­
dress a specific type of derivative. The procedures in those 
sections are to be performed only if the insurance com­
pany entered into derivative transactions of the type cov­
ered by the section. Sections that address types of 
derivatives not used by the insurance company should not 
be attached to the agreed-upon procedures report.
23. If any portion of a procedure results in an exception, the 
findings for that entire procedure should be recorded as an 
exception and described in the section “Description of Ex­
ceptions If Any,” at the end of each section. The practi­
tioner should provide a brief factual explanation for each 
exception that will enable the specified parties to under­
stand the nature of the findings resulting in the exception. 
If management informs the practitioner that the condition 
giving rise to the exception was corrected by the date of the 
practitioner’s report, the practitioner’s explanation of the 
exception may include that information; for example, 
“Management has advised us that the condition resulting in 
the exception was corrected on Month X, 20XX. We have 
performed no procedures with respect to management’s as­
sertion.”
24. A  practitioner may perform significant portions of the 
agreed-upon procedures engagement before the end of the 
period covered by the report. If, during that time, the prac­
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titioner identifies conditions that result in an exception in 
one or more agreed-upon procedures, he or she should re­
port the exception in the findings section of the agreed- 
upon procedures report, even if management corrects the 
condition prior to the end of the period.
25. The Law requires the insurance company to provide the 
Department with a statement describing the independent 
CPA’s assessment of the insurance company’s internal con­
trol over derivative transactions. It also requires the insur­
ance company to include a description of any remedial 
actions taken or proposed to be taken to correct any defi­
ciencies identified by the independent CPA.
26. AT Section 201.40 states the following.
The practitioner need not perform procedures beyond 
the agreed-upon procedures. However, in connection 
with the application of agreed-upon procedures, if mat­
ters come to the practitioner’s attention by other means 
that significantly contradict the subject matter (or writ­
ten assertion related thereto) referred to in the practi­
tioner’s report, the practitioner should include this 
matter in his or her report. For example, if during the 
course of applying agreed-upon procedures regarding an 
entity’s internal control, the practitioner becomes aware 
of a material weakness by means other than perfor­
mance of the agreed-upon procedures, the practitioner 
should include this matter in his or her report.
27. A  practitioner has no obligation to perform procedures be­
yond the agreed-upon procedures included in Appendix B 
of this SOP. However, if information indicating a weakness 
in internal control over derivative transactions comes to 
the practitioner’s attention by other means, such informa­
tion should be included in the practitioner’s report. This 
would apply to conditions or events occurring during the 
subsequent-events period (subsequent to the period cov­
ered by the practitioner’s report but prior to the date of the 
practitioner’s report) that either contradict the findings in 
the report or that would have resulted in the reporting of 
an exception by the practitioner if that condition or event 
had existed during the period covered by the report. How­
ever, the practitioner has no responsibility to perform any 
procedure to detect such conditions or events.
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Establishing an Understanding 
W ith the Client
28. In accordance with AT Section 201.10, the practitioner 
should establish an understanding with the client regarding 
the services to be performed. Such an understanding re­
duces the risk that the client may misinterpret the objec­
tives and limitations of an agreed-upon procedures 
engagement performed to meet the regulatory require­
ments of the Law. Such an understanding also reduces the 
risk that the client will misunderstand its responsibilities 
and the responsibilities of the practitioner. The practi­
tioner should document the understanding in the working 
papers, preferably through a written communication with 
the client (an engagement letter). The communication 
should be addressed to the client. Matters that might be in­
cluded in such an understanding are the following:
• A  statement confirming that an agreed-upon proce­
dures engagement is to be performed to meet the re­
quirements of Section 1410(b)(5) of the Law
• A  statement identifying the procedures to be per­
formed as those set forth in SOP 01-3, Performing 
Agreed-Upon Procedures Engagements That Ad ­
dress Internal Control Over Derivative Transac­
tions as Required by the New York State Insurance 
Law
• A  statement identifying the client as the specified 
party to the agreed-upon procedures report
• A  statement acknowledging the client’s responsibil­
ity for the sufficiency of the procedures in the SOP
• A  statement acknowledging that the practitioner 
makes no representation regarding the sufficiency of 
the procedures in the SOP
• A  statement describing the responsibilities of the 
practitioner, including but not limited to the respon­
sibility to perform the agreed-upon procedures and 
to provide the client with a report, and the circum­
stances under which the practitioner may decline to 
issue a report
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• A statement indicating that the engagement will be 
conducted in accordance with attestation standards 
established by the American Institute of Certified 
Public Accountants (AICPA)
• A  statement indicating that an agreed-upon proce­
dures engagement does not constitute an examina­
tion, the objective of which would be the expression 
of an opinion on the internal control over derivative 
transactions, and that if an examination were per­
formed, other matters might come to the practi­
tioner’s attention
• A  statement indicating that the practitioner will not 
express an opinion or any other form of assurance
• A  statement describing the client’s responsibility to 
comply with the Law and the client’s responsibility 
for the design and operation of effective internal con­
trol over derivative transactions
• A  statement describing the client’s responsibility for 
providing accurate and complete information to the 
practitioner
• A  statement indicating that the practitioner has no 
responsibility for the completeness or accuracy of 
the information provided to the practitioner
• A statement restricting the use of the report to the 
client
• A statement describing any arrangements to involve 
a specialist
M anagem ent Representations
29. Although AT Section 201 does not require a practitioner to 
obtain a representation letter from management in an 
agreed-upon procedures engagement, it is recommended 
that the practitioner obtain such a letter when performing 
the engagement described in this SOP. The representation 
letter generally should be signed by the appropriate mem­
bers of management including the highest ranking officer 
responsible for internal control over derivative transac-
1 8
tions. Management’s refusal to furnish written representa­
tions that the practitioner has determined to be appropri­
ate for the engagement constitutes a limitation on the 
performance of the engagement that requires either modi­
fication of the report or withdrawal from the engagement.
30. The representations that a practitioner deems appropriate 
will depend on the specific nature of the engagement; how­
ever, the practitioner ordinarily would obtain the following 
representations from management:
• A statement acknowledging responsibility for estab­
lishing and maintaining effective internal control 
over derivative transactions
• A statement that there have been no errors or fraud 
that might indicate a weakness in the internal con­
trol over derivative transactions
• A statement that management has disclosed to the 
practitioner all significant deficiencies in the design 
or operation of the internal control over derivative 
transactions
• A statement that management has disclosed to the 
practitioner any communications from regulatory 
agencies, internal auditors, and other practitioners 
or consultants relating to the internal control over 
derivative transactions
• A statement that management has made available to 
the practitioner all information they believe is rele­
vant to the internal control over derivative transac­
tions
• A statement that management has responded fully to 
all inquiries made by the practitioner during the en­
gagement
• A statement that no events have occurred subse­
quent to the date as of which the procedures were 
applied that would require adjustment to or modifi­
cation to responses to the agreed-upon procedures
31. An illustrative representation letter is presented in appen­
dix C, “Illustrative Management Representation Letter,”of
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this SOP. For additional information regarding manage­
ment’s representations in an agreed-upon procedures en­
gagement, see AT Sections 201.37-39.
Restriction on the Performance of 
Procedures
32. As previously stated, a practitioner should not agree to do 
either of the following.
a. Eliminate any of the procedures presented in appen­
dix B of this SOP, unless a section is not applicable 
because the insurance company did not enter into 
derivative transactions addressed by the section.
b. Reduce the extent of the tests in an applicable sec­
tion.
33. If circumstances impose restrictions on the performance of 
the agreed-upon procedures presented in appendix B of 
this SOP, the practitioner should describe the restriction(s) 
in his or her report or withdraw from the engagement.
Dating the Report
34. The date of completion of the agreed-upon procedures 
should be used as the date of the practitioner’s report.
Effective Date
35. This SOP is effective upon issuance and is applicable only 
to agreed-upon procedures engagements that address in­
ternal control over derivative transactions required by the 
Law.
20
APPENDIX A
Illustrative Agreed-Upon Procedures 
Report
The following is an illustrative agreed-upon procedures re­
port based on the guidance in AT Section 201, “Agreed- 
Upon Procedures Engagements,” in Statement on 
Standards for Attestation Engagements (SSAE) No. 10, At­
testation Standards: Revision and Recodification (AIPCA, 
Professional Standards, vol. 2, AT sec. 201).
Independent Accountant’s Report 
on Applying Agreed-Upon Procedures
To the Management of ABC Insurance Company:
We have performed the applicable procedures enumer­
ated in the American Institute of Certified Public Ac­
countants’ Statement of Position (SO P), 01-3, 
Performing Agreed-Upon Procedures Engagements That 
Address Internal Control Over Derivative Transactions 
as Required by the New York State Insurance Law, 
which were agreed to by ABC Insurance Company, solely 
to assist you in complying with the requirements of Sec­
tion 1410 (b )(5 ) of the New York State Insurance Law, as 
amended (the Law), which addresses the assessment of 
internal control over derivative transactions as defined 
in Section 1401(a) of the Law, and Section 178.6(b) of 
Regulation No. 163 during the year ended December 31, 
20XX. Management of ABC Insurance Company is re­
sponsible for maintaining effective internal control over 
derivative transactions. This agreed-upon procedures 
engagement was conducted in accordance with attesta­
tion standards established by the American Institute of 
Certified Public Accountants. The sufficiency of these 
procedures is solely the responsibility of ABC Insurance 
Company. Consequently, we make no representation re­
garding the sufficiency of the procedures described in 
the attached Appendix either for the purpose for which 
this report has been requested or for any other purpose.
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The procedures performed and the findings are included 
in the attached Appendix.
We were not engaged to and did not conduct an exami­
nation, the objective of which would be the expression of 
an opinion on the internal control over derivative trans­
actions of ABC Insurance Company for the year ended 
December 31, 20XX. Accordingly, we do not express 
such an opinion. Had we performed additional proce­
dures, other matters might have come to our attention 
that would have been reported to you.
This report is intended solely for the information and use 
of the management and Board of Directors of ABC Insur­
ance Company and is not intended to be and should not 
be used by anyone other than these specified parties.
[Signature]
[Date]
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APPENDIX B
Agreed-Upon Procedures for Testing 
Internal Control Over Derivative 
Transactions
The following table lists the types of derivative transactions 
permitted by the New York Derivative Law (the Law). We 
inquired of management of the insurance company as to 
whether the insurance company used the type of derivative 
addressed by each section, and marked the column enti­
tled “Is the Section Applicable?” either Yes or No based on 
management’s response to the inquiry. For each type of de­
rivative with a Yes response, we performed the procedures 
in the applicable section and attached the section to the re­
port. For each type of derivative with a No response, we did 
not perform procedures nor did we attach the applicable 
section to the report. We compared the types of derivative 
reported by the insurance company in its “Schedule of De­
rivative Transactions” included in the Annual Statement 
with the types of derivatives listed in the following table 
and found that the types of derivatives included in the 
schedule were marked Yes in the table.
Attachments to the Report
Section of the Is the Section
Agreed-Upon Procedures Applicable?
No. Type of Derivative Yes or No
1 All Derivative Types Yes
2 Gap Contracts
3 Collar Contracts
4 Floor Contracts
5 Forward Contracts
6 Future Contracts
7 Option Contracts
8 Swap Contracts
9 Swaption Contracts
10 Warrant Contracts
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Section 1— All Derivative Types
Procedures
The following procedures were performed to 
test controls applicable to all derivative 
transactions. The procedures were applied 
to the internal control over derivative trans­
actions in existence during the year ended 
December 31, 20XX.
Documentation of Controls, Policies, and 
Procedures
1. Read the insurance company’s derivative 
use plan (DUP), amendments thereto, 
and its documentation of controls, poli­
cies, and procedures that describe inter­
nal control over derivative transactions 
and found that the DUP and the docu­
mentation of controls, policies, and pro­
cedures include a description of controls 
that address the following:
a. Systems or processes for the periodic 
valuation of derivative transactions in­
cluding mechanisms for compensating 
for any lack of independence in valu­
ing derivative positions (Valuation)
b. Systems or processes for determining 
whether a derivative instrument used 
for hedging or replication has been ef­
fective (Effectiveness)
c. Credit risk management systems or 
processes for over-the-counter (OTC) 
derivative transactions that measure 
credit risk exposure using the coun­
terparty exposure amount and poli­
cies for the establishment of collateral 
arrangements with counterparties 
(Credit Risk Management)
d. Management assessment of the ade­
quacy and technical expertise of per­
sonnel associated with derivative 
transactions and systems to imple­
ment and control investment practices
Findings
No
Exception Exception N/A
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Procedures Exception Exception N/A
involving derivatives (Professional 
Competence)
e. Systems or processes for regular re­
ports to management, segregation of 
duties, and internal review procedures 
(Reporting)
f. Procedures for conducting initial and 
ongoing legal reviews of derivative 
transactions including assessments of 
contract enforceability (Legal Reviews)
Nontransaction-Specific Procedures
2 Read the minutes of meetings of the 
board of directors and found an indica­
tion that the board of directors of the in­
surance company approved the DUP and 
any amendments thereto.
3. Inquired of management as to whether 
the DUP and any amendments thereto 
were approved by the New York State In­
surance Department and was advised 
that the DUP and any amendments 
thereto were approved.
4. Read the minutes of meetings of the 
board of directors and found an indica­
tion that the board of directors of the 
insurance company approved the com­
mitment of financial resources deter­
mined by management to be sufficient 
to accomplish the objectives of the in­
surance company’s DUP.
This procedure does not provide an assess­
ment o f or assurance about the adequacy of 
the resources determined by management 
to be sufficient to accomplish the objectives 
of the DUP.
In performing the following procedures, the 
practitioner should be aware that manage­
ment frequently w ill have designated and
(continued)
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will have in place limits, controls, or proce­
dures that are more restrictive than those 
approved for use in the DUP.
5. For the year ended December 31, 20XX,
inquired of management and was ad­
vised that —
a. There was monitoring of derivative 
transactions by a control staff, such as 
internal audit or other internal review 
group, that is independent of deriva­
tives trading activities.
b. There were procedures in place for 
derivative personnel to obtain, prior 
to exceeding limits prescribed by 
management, at least oral approval 
from members of senior management 
who are independent of derivatives 
trading activities.
c. There were procedures in place for se­
nior management to address excesses 
related to management-established 
limits and divergences from manage­
ment-approved derivative strategies, 
and that such management has au­
thority to grant exceptions to deriva­
tives limits.
d. There were procedures in place re­
quiring that management be informed 
when limits prescribed in the DUP 
were exceeded and for management to 
approve corrective action(s) in such 
circumstances.
e. There were procedures in place for 
the accurate transmittal of derivatives 
positions to the risk measurement 
systems when management had im­
plemented risk management systems.
f. There were procedures in place for 
the performance of appropriate recon­
ciliations to ensure data integrity
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across the full range of derivatives, in­
cluding any new or existing deriva­
tives that may be monitored apart 
from the main processing networks.
g. There were procedures in place for 
risk managers and senior manage­
ment to define constraints on deriva­
tive activities to ensure compliance 
with the DUP and to justify excesses 
with respect to specified management 
limits.
h. There were procedures in place for se­
nior management, an independent 
group, or an individual that manage­
ment designated to perform at least an 
annual assessment of the identified 
controls and financial results of the de­
rivative activities to determine that 
controls were effectively implemented 
and that the insurance company’s 
business objectives and strategies were 
achieved.
i. There were procedures in place for a 
review of limits in the context of 
changes in strategy, risk tolerance of 
the insurance company, and market 
conditions.
Reporting to the Board of Directors or 
Committee Thereof
The Law contains provisions regarding man­
agement oversight of derivative and replica­
tion transactions.
6. Read the minutes of the board of direc­
tors meetings or committees thereof and 
found an indication that the board of di­
rectors or committee thereof received, 
at least quarterly, a report regarding de­
rivative and replication transactions.
(continued)
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7. Read one quarterly report referred to in 
procedure 6 and found that the report 
contained—
a. A list, or appropriate summaries, of 
the following:
i. Derivative transactions during the 
period
ii. Derivative transactions outstand­
ing at the end of the period
iii. Unrealized gains or losses on open 
derivative positions
iv. Derivative transactions closed dur­
ing the period
b. A summary of the performance of the 
derivatives in comparison to the ob­
jective of the derivative transactions
c. An evaluation of the risks and benefits 
of the derivative transactions
d. A summary of the amount, type, and 
performance of replication transac­
tions
8. If the report referred to in the preceding 
procedure was received, reviewed, and 
approved by a committee of the board of 
directors, read the minutes of the board 
of directors meeting and found an indi­
cation that a report of such committee 
was reviewed at the next board of direc­
tors meeting.
9. Read the board of directors minutes and 
found an indication that the board of di­
rectors received a report during the year 
describing the level of knowledge and 
experience of individuals conducting, 
monitoring, controlling, and auditing de­
rivative and replication transactions.
Procedures
Findings
No
Exception Exception N/A
Derivative and Replication Limitations
The Law contains limits on hedging and 
replication transactions. An insurance com­
pany may enter into hedging or replication 
transactions if, as a result of and after giving 
effect to the transaction, the derivative in­
vestments and replication investments do 
not exceed certain specified percentages of 
admitted assets. The following procedures 
were performed using one analysis per quar­
ter prepared by the insurance company to 
monitor compliance with the limitations.
10. Obtained and read the insurance com­
pany’s analysis used to test limitations 
on investments in derivatives and repli­
cation transactions and found that the 
amounts shown in the analysis indicated 
that—
a. The aggregate statement value of op­
tions, swaptions, caps, floors, and war­
rants purchased was not in excess of 
seven and one-half percent of the in­
surance company’s admitted assets,
per the last annual statement. _________  __________  _________
b. The aggregate statement value of op­
tions, swaptions, caps, and floors writ­
ten was not in excess of three percent
of admitted assets. _________  __________  _________
c. The aggregate potential exposure of 
collars, swaps, forwards, and futures 
entered into and options, swaptions, 
caps, and floors written was not in ex­
cess of six and one-half percent of ad­
mitted assets. _________  __________  _________
d. The aggregate statement value of all 
assets being replicated did not exceed 
ten percent of the insurance com­
pany’s admitted assets. _________  __________  _________
e. The extent of derivative transactions 
did not exceed the insurance com-
(continued)
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pany’s internal limitations or that any 
excess had been specifically autho­
rized by management.
11. Inquired of the preparer of the analysis 
read in procedure 10 and was advised 
that the analysis excluded transactions 
entered into to hedge the currency risk 
of investments denominated in a cur­
rency other than United States dollars.
12. Obtained and read the insurance com­
pany’s analysis used to test limitations 
on counterparty exposure, as defined in 
section 178.3 (e) of the Regulation, and 
found that the report indicated that—
a. The counterparty exposure under one 
or more derivative transactions for 
any single counterparty, other than a 
“qualified counterparty,” was not in 
excess of one percent of the insurance 
company’s admitted assets.
b. The counterparty exposure under one 
or more derivative transactions for all 
counterparties, other than qualified 
counterparties, was not in excess of 
three percent of the insurance com­
pany’s admitted assets.
13. If the insurance company required collat­
eral arrangements with the counterpar­
ties, obtained and read the insurance 
company’s analysis used to monitor the 
adequacy of the collateral held in accor­
dance with the terms of the arrangement 
and found that the amount of the collateral 
held as shown on the analysis was equal to 
or in excess of the amount to be held.
Description of Exceptions if Any
Procedure Number Description of Exception
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Section 2— Cap Contracts
Findings
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Procedures Exception Exception N/A
Performed the following procedures on se­
lected cap contracts to test internal control 
over cap transactions. Selected five percent of 
each type of cap transaction (that is, pur­
chases [premium disbursements], sales [pre­
mium receipts], and closeouts [closings and 
settlings of the position]), with the selections 
distributed throughout the year. If five percent 
of a given type of transaction exceeded 40, the 
number of items selected for that type of trans­
action was limited to 40. If five percent of a 
type of transaction resulted in less than four 
items, selected four or fewer items that repre­
sented all the transactions of that type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to enter
into cap contracts. ------------  -------------  ------------
2. For each cap selected for testing, read 
management’s documentation describ­
ing the intended use of the cap and per­
formed the following procedures, as
applicable. ------------  -------------  ------------
For caps used as a hedge—
3. Determined that the documentation de­
scribed the following:
a. The risk hedged ------------  -------------  ------------
b. How the hedge was consistent with
the overall risk management strategy ------------  -------------  ------------
c. How the cap was expected to be effec­
tive in offsetting the exposure ------------  -------------  ------------
d. The approach in assessing the effec­
tiveness of the hedge _________  __________  _________
(continued)
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4. Determined that the following items were
documented:
a. The purpose(s) of the cap as a hedge
b. The terms of the cap, the name of the 
counterparty, and the counterparty 
exposure amount
c. The assets or liabilities (or portion 
thereof) that the cap hedged
d. Evidence that the cap continued to be 
an effective hedge
e. Evidence that the cap was consistent 
with the insurance company’s para­
meters, as specified in the DUP or ap­
plicable company policies and 
procedures, for entering into hedge 
transactions; for example, the no­
tional amount or underlying
If the cap was an exact offset to an outstand­
ing cap—
5. Read documentation indicating that the 
cap offset an outstanding cap previously 
purchased or sold by the insurance com­
pany and that the cap was an exact off­
set of the market risk of the cap being 
offset.
For caps used in a replication transaction—
6. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated
b. How the replication was consistent 
with the overall management invest­
ment strategy
c. How the cap was expected to be effec­
tive in replicating the investment 
characteristics of the replicated in­
vestment
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d. The approach for assessing the effec­
tiveness of the replication transaction
7. Determined that the following items 
were documented:
a. The instruments used in the replica­
tion and the investment type and 
characteristics replicated
b. The terms of the cap, the name of the 
counterparty, and the counterparty 
exposure amount
For all selected caps including those that are
a part of a replication transaction—
8. Obtained a list of individuals, approved 
by the board of directors or a committee 
thereof, who had the authority to autho­
rize cap transactions. Compared the 
name of the individual who authorized 
the cap transaction with the names on 
the list and found the name of the indi­
vidual on the list.
9. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s 
policy regarding the requirement for the 
board of directors or a committee 
thereof to authorize the specific transac­
tion tested; for example, a transaction in 
which the notional amount or strike 
price exceeded a limit requiring addi­
tional approval. If the board of directors 
or a committee thereof was required to 
approve the transaction, read minutes of 
the board of directors or a committee 
thereof or other appropriate support and 
found evidence of approval of the trans­
action tested.
10. Obtained a list of qualified and non­
qualified counterparties, approved by 
the board of directors or a committee
(continued)
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thereof. Compared the name of the 
counterparty involved in the cap trans­
action with names on the list and found 
the name of the counterparty on the re­
spective qualified or nonqualified list.
11. Determined that the counterparty was 
listed as qualified or nonqualified in the 
analysis used for monitoring the insur­
ance company’s limitations on counter­
party exposure consistent with the 
classification in the listing obtained in 
procedure 10.
12. Obtained a list of individuals authorized 
by the board of directors or a committee 
thereof to trade cap contracts. Com­
pared the name of the individual who 
executed the purchase, sale, or closeout 
of the cap with the names on the list and 
found the name of the individual on the 
list.
13. Obtained a list of individuals authorized 
to approve payments relating to caps. 
Compared the name of the individual 
who approved any payment relating to 
the cap with the names on the list and 
found the name of the individual on the 
list.
14. Compared the name of the individual 
who approved any payment relating to 
the cap with the name of the individual 
who approved entering into the contract 
and found that the names were different.
15. Compared the name of the individual 
who received cash or other considera­
tion in connection with the cap with the 
name of the individual who entered into 
the contract and found that the names 
of the individuals were different.
16. Obtained the deal ticket and confirma­
tion for the purchase, sale, or closeout of 
the cap and found that the purchase,
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sale, or closeout was confirmed by the 
counterparty.
17. Compared the name of the individual 
who received the deal ticket and confir­
mation with the names on a list of indi­
viduals authorized to trade caps and 
found that the name was not on the list.
18. Compared the terms of the cap contract, 
as stated on the deal ticket and confir­
mation, with the terms of the cap con­
tract recorded in the insurance 
company’s accounting records and 
found them to be in agreement.
19. Obtained documentation for one report­
ing period (for example, monthly or 
quarterly), indicating that the insurance 
company determined that its accounting 
records for caps tested in procedure 18, 
agreed with or reconciled to the related 
control account; for example, the sub­
sidiary ledger to the general ledger.
20. Obtained the accounting record docu­
menting modifications, if any, to the cap 
agreement. Compared the name of the 
individual who approved the modifica­
tion with a list of individuals authorized 
to approve modifications and found the 
name of the individual who approved 
the modification on the list.
21. Compared the terms of the cap agree­
ment recorded in the insurance com­
pany’s accounting records with the 
terms shown in the executed copy of the 
cap agreement and found them to be in 
agreement.
22. Obtained documentation for one report­
ing period (for example, monthly or 
quarterly), indicating that the insurance 
company physically inventoried the cap 
agreements.
(continued)
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23. Using the list of authorized traders ob­
tained in procedure 12, compared the 
name of the individual who had custody 
or access to the cap agreement with the 
names of individuals authorized to exe­
cute purchases, sales, or closeouts of cap 
contracts and found that the name of 
the individual was not on the list.
24. Compared information regarding the 
cap, such as type of derivative, notional 
amount, and fair value, with the compa­
rable information included in the report 
to the board of directors or appropriate 
committee thereof and found them to be 
in agreement.
25. If the cap should have been included in 
the monitoring analysis separately 
tested in procedure 10 within section 1, 
“All Derivative Types,” compared infor­
mation regarding the cap, such as type 
of derivative, notional amount, and fair 
value, with the comparable information 
in the monitoring analysis and found 
them to be in agreement.
26. Read accounting documentation indi­
cating that the insurance company mon­
itored periodic cash settlements related 
to the cap tested, meaning, the insur­
ance company had controls in place to 
determine that periodic cash settle­
ments, if any, were received.
Effectiveness of Caps Used As Hedges and in
Replication Transactions
27. Read the insurance company’s docu­
mentation of effectiveness and found 
that the insurance company evaluated 
the effectiveness of the cap as a hedge or 
replication in accordance with the poli­
cies regarding effectiveness.
28. If the cap was no longer effective as a 
hedge or replication, compared the ac-
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tion taken by the insurance company 
with the action required by the account­
ing policies and procedures and found 
that the action taken was consistent 
with the accounting policy.
Legal Review
29. Read documentation indicating that the 
legal department reviewed the cap 
agreement to assess contract compli­
ance with the DUP and enforceability.
30. Read documentation indicating that the 
legal department updated its assessment 
of agreement enforceability at least an­
nually.
Valuation
31. Obtained the insurance company’s poli­
cies and procedures for valuing caps and 
found that the insurance company de­
termined the fair value of the cap in ac­
cordance with the policy described in 
the insurance company’s procedures for 
the valuation of caps.
32. Read documentation supporting the fair 
value of the cap and found that the fair 
value was either (a) obtained from an in­
dependent source, (b) checked against 
an independent source, or (c) calculated 
internally by an authorized person.
Description of Exceptions if Any
Procedure Number Description of Exception
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Performed the following procedures on se­
lected collar contracts to test internal con­
trol over collar transactions. Selected five 
percent of each type of collar transaction 
(that is, executions [entering into a collar 
transaction in which the net position at in­
ception may result in either no cash outlay, 
cash received, or cash disbursed] and close­
outs [closings and settlings of the position]), 
with the selections distributed throughout 
the year. If five percent of a given type of 
transaction exceeded 40, the number of 
items selected for that type of transaction 
was limited to 40. If five percent of a type of 
transaction resulted in less than four items, 
selected four or fewer items that repre­
sented all the transactions of that type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to enter 
into collar contracts.
2. For each collar selected for testing, read 
management’s documentation describ­
ing the intended use of the collar and 
performed the following procedures, as 
applicable.
For collars used as a hedge—
3. Determined that the documentation de­
scribed the following:
a. The risk hedged
b. How the hedge was consistent with 
the overall risk management strategy
c. How the collar was expected to be ef­
fective in offsetting the exposure
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d. The approach in assessing the effec­
tiveness of the hedge ------------  -------------  ------------
4. Determined that the following items 
were documented:
a. The purpose(s) of the collar as a hedge _________  __________  _________
b. The terms of the collar, the name of 
the counterparty, and the counter­
party exposure amount ------------  -------------  ------------
c. The assets or liabilities (or portion
thereof) that the collar hedged _________  __________  _________
d. Evidence that the collar continued to
be an effective hedge _________  __________  _________
e. Evidence that the contract was consis­
tent with the insurance company’s pa­
rameters, as specified in the DUP or 
applicable company policies and pro­
cedures, for entering into hedge trans­
actions; for example, the notional
amount or underlying _________  __________  _________
If the collar was an exact offset of an out­
standing collar—
5. Read documentation indicating that the 
collar offset an outstanding collar previ­
ously purchased or sold by the insur­
ance company and that the collar was an 
exact offset of the market risk of the col­
lar being offset. _________  __________  _________
For collars used in a replication transac­
tion—
6. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated _________  __________  _________
b. How the replication was consistent 
with the overall management invest­
ment strategy _________  __________  _________
(continued)
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c. How the collar was expected to be ef­
fective in replicating the investment 
characteristics of the replicated in­
vestment
d. The approach in assessing the effec­
tiveness of the replication transaction
7. Determined that the following items 
were documented:
a. The instruments used in the replica­
tion and the investment type and 
characteristics replicated
b. The terms of the collar, the name of 
the counterparty, and the counter­
party exposure amount
For all selected collars including those that
are a part of a replication transaction—
8. Obtained a list of individuals, approved 
by the board of directors or a committee 
thereof, who had the authority to autho­
rize collar transactions. Compared the 
name of the individual who authorized 
the collar transaction with the names on 
the list and found the name of the indi­
vidual on the list.
9. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s 
policy regarding the requirement for the 
board of directors or a committee 
thereof to authorize the specific transac­
tion tested; for example, a transaction in 
which the notional amount or strike 
price exceeded a limit requiring addi­
tional approval. If the board of directors 
or a committee thereof was required to 
approve the transaction, read minutes of 
the board of directors or a committee 
thereof or other appropriate support and
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found evidence of approval of the trans­
action tested. _________  __________  _________
10. Obtained a list of qualified and nonqual­
ified counterparties approved by the 
board of directors or a committee 
thereof. Compared the name of the 
counterparty involved in the collar trans­
action with names on the list and found 
the name of the counterparty on the re­
spective qualified or nonqualified list. ------------  -------------  ------------
11. Determined that the counterparty was 
listed as qualified or nonqualified in the 
analysis used for monitoring the insur­
ance company’s limitations on counter­
party exposure consistent with the 
classification in the listing obtained in
procedure 10. _________  __________  _________
12. Obtained a list of individuals authorized 
by the board of directors or a committee 
thereof to trade collar contracts. Com­
pared the name of the individual who 
executed the execution or closeout of 
the collar contract with the names on 
the list and found the name of the indi­
vidual on the list. _________  __________  _________
13. Obtained a list of individuals authorized 
to approve payments relating to collars.
Compared the name of the individual who 
approved any payment relating to the col­
lar with the names on the list and found
the name of the individual on the list. ------------  -------------  ------------
14. Compared the name of the individual 
who approved any payment relating to 
the collar with the name of the individ­
ual who approved entering into the con­
tract and found that the names were
different. ------------  -------------  ------------
15. Compared the name of the individual 
who received cash or other considera­
tion in connection with the collar with 
the name of the individual who entered
(continued)
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into the contract and found that the 
names of the individuals were different.
16. Obtained the deal ticket and confirma­
tion for the execution or closeout of the 
collar and found that the execution or 
closeout was confirmed by the counter­
party.
17. Compared the name of the individual 
who received the deal ticket and confir­
mation with the names on a list of indi­
viduals authorized to trade collars and 
found that the name was not on the list.
18. Compared the terms of the collar con­
tract, as stated on the deal ticket and 
confirmation, with the terms of the col­
lar contract recorded in the insurance 
company’s accounting records and 
found them to be in agreement.
19. Obtained documentation for one report­
ing period (for example, monthly or 
quarterly), indicating that the insurance 
company determined that its accounting 
records for collars, tested in procedure
18, agreed with or reconciled to the re­
lated control account; for example, the 
subsidiary ledger to the general ledger.
20. Obtained the accounting record docu­
menting modifications, if any, to the col­
lar agreement. Compared the name of 
the individual who approved the modifi­
cation with a list of individuals autho­
rized to approve modifications and 
found the name of the individual who 
approved the modification on the list.
21. Compared the terms of the collar agree­
ment recorded in the insurance com­
pany’s accounting records with the 
terms shown in the executed copy of the 
collar agreement and found them to be 
in agreement.
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22. Obtained documentation for one report­
ing period (for example, monthly or 
quarterly), indicating that the insurance 
company physically inventoried the col­
lar agreement.
23. Using the list of authorized traders ob­
tained in procedure 12, compared the 
name of the individual who had custody 
or access to the collar contracts with the 
names of individuals authorized to enter 
into trades, executions, or closeouts of 
collar contracts and found that the name 
of the individual was not on the list.
24. Compared information regarding the 
collar, such as type of derivative, no­
tional amount, and fair value, with the 
comparable information included in the 
report to the board of directors or appro­
priate committee thereof and found 
them to be in agreement.
25. If the collar should have been included 
in the monitoring analysis separately 
tested in procedure 10 within section 1, 
“All Derivative Types,” compared infor­
mation regarding the collar, such as type 
of derivative, notional amount, and fair 
value, with the comparable information 
in the monitoring analysis and found 
them to be in agreement.
26. Read accounting documentation indi­
cating that the insurance company mon­
itored periodic cash settlements related 
to the collar tested, meaning, the insur­
ance company had controls in place to 
determine that periodic cash settle­
ments, if any, were received.
Effectiveness of Collars Used As Hedges and
in Replication Transactions
27. Read the insurance company’s docu­
mentation of effectiveness and found 
that the insurance company evaluated
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the effectiveness of the collar as a hedge 
or replication in accordance with the 
policies regarding effectiveness.
28. If the collar was no longer effective as a 
hedge or replication, compared the ac­
tion taken by the insurance company 
with the action required by the account­
ing policies and procedures and found 
that the action taken was consistent 
with the accounting policy.
Legal Review
29. Read documentation indicating that the 
legal department reviewed the collar 
agreement to assess contract compli­
ance with the DUP and enforceability.
30. Read documentation indicating that the 
legal department updated its assessment 
of agreement enforceability at least an­
nually.
Valuation
31. Obtained the insurance company’s poli­
cies and procedures for valuing collars 
and found that the insurance company 
determined the fair value of the collar in 
accordance with the policy described in 
the insurance company’s procedures for 
the valuation of collars.
32. Read documentation supporting the fair 
value of the collar and found that the fair 
value was either (a) obtained from an in­
dependent source, (b) checked against 
an independent source, or (c) calculated 
internally by an authorized individual.
Description of Exceptions if Any
Procedure Number Description of Exception
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Performed the following procedures on se­
lected floor contracts to test internal control 
over floor transactions. Selected five percent 
of each type of floor transaction (that is, pur­
chases [premium disbursements], sales [pre­
mium receipts], and closeouts [closings and 
settlings of the position]), with the selections 
distributed throughout the year. If five percent 
of a given type of transaction exceeded 40, the 
number of items selected for that type of trans­
action was limited to 40. If five percent of a 
type of transaction resulted in less than four 
items, selected four or fewer items that repre­
sented all the transactions of that type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to enter
into floor contracts. _________  __________  _________
2. For each floor selected for testing, read 
management’s documentation describ­
ing the intended use of the floor and per­
formed the following procedures, as
applicable. _________  __________  _________
For floors used as a hedge—
3. Determined that the documentation de­
scribed the following:
a. The risk hedged _________  __________  _________
b. How the hedge was consistent with
the overall risk management strategy _________  __________  _________
c. How the floor was expected to be ef­
fective in offsetting the exposure _________  __________  _________
d. The approach in assessing the effec­
tiveness of the hedge _________  __________  _________
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45
Procedures
No
Exception Exception N/A
4. Determined that the following items 
were documented:
a. The purpose(s) of the floor as a hedge
b. The terms of the floor, the name of the 
counterparty, and the counterparty 
exposure amount
c. The assets or liabilities (or portion 
thereof) that the floor hedged
d. Evidence that the floor continued to 
be an effective hedge
e. Evidence that the floor was consistent 
with the insurance company’s parame­
ters, as specified in the DUP or applic­
able company policies and procedures 
for entering into hedge transactions; 
for example, the notional amount or 
underlying
If the floor was an exact offset of an out­
standing floor—
5. Read documentation indicating that the 
floor offset an outstanding floor previ­
ously purchased or sold by the insur­
ance company and that the floor was an 
exact offset of the market risk of the 
floor being offset.
For floors used in a replication transac­
tion—
6. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated
b. How the replication was consistent 
with the overall management invest­
ment strategy
c. How the floor was expected to be effec­
tive in replicating the investment char­
acteristics of the replicated investment
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d. The approach in assessing the effec­
tiveness of the replication transaction _________  __________  _________
7. Determined that the following items were
documented:
a. The instruments used in the replica­
tion and the investment type and
characteristics replicated _________  __________  _________
b. The terms of the floor, the name of the 
counterparty, and the counterparty
exposure amount _________  __________  _________
For all selected floors including those that
are a part of a replication transaction—
8. Obtained a list of individuals approved 
by the board of directors or a committee 
thereof who had the authority to autho­
rize floor transactions. Compared the 
name of the individual who authorized 
the floor transaction with the names on 
the list and found the name of the indi­
vidual on the list. _________  __________  _________
9. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s 
policy regarding the requirement for the 
board of directors or a committee 
thereof to authorize the specific transac­
tion tested; for example, a transaction in 
which the notional amount or strike 
price exceeded a limit requiring addi­
tional approval. If the board of directors 
or a committee thereof was required to 
approve the transaction, read minutes of 
the board of directors or a committee 
thereof or other appropriate support and 
found evidence of approval of the trans­
action tested. _________  __________  _________
10. Obtained a list of qualified and non­
qualified counterparties, approved by 
the board of directors or a committee
(continued)
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thereof. Compared the name of the 
counterparty involved in the floor trans­
action with names on the list and found 
the name of the counterparty on the re­
spective qualified or nonqualified list.
11. Determined that the counterparty was 
listed as qualified or nonqualified in the 
analysis used for monitoring the insur­
ance company’s limitations on counter­
party exposure consistent with the 
classification in the listing obtained in 
procedure 10.
12. Obtained a list of individuals authorized 
by the board of directors or a committee 
thereof to trade floor contracts. Com­
pared the name of the individual who 
executed the purchase, sale, or closeout 
of the floor with the names on the list 
and found the name of the individual on 
the list.
13. Obtained a list of individuals authorized 
to approve payments relating to floors. 
Compared the name of the individual 
who approved any payment relating to 
the floor with the names on the list and 
found the name of the individual on the 
list.
14. Compared the name of the individual 
who approved any payment relating to 
the floor with the name of the individual 
who approved entering into the contract 
and found that the names were different.
15. Compared the name of the individual 
who received cash or other considera­
tion in connection with the floor with 
the name of the individual who entered 
into the contract and found that the 
names of the individuals were different.
16. Obtained the deal ticket and confirma­
tion for the purchase, sale, or closeout of 
the floor and found that the purchase,
4 8
Findings
No
Findings
sale, or closeout was confirmed by the
counterparty. _________  __________  _________
17 Compared the name of the individual 
who received the deal ticket and confir­
mation with the names on a list of indi­
viduals authorized to trade floors and
found that the name was not on the list. ------------  -------------  ------------
18. Compared the terms of the floor con­
tract, as stated on the deal ticket and 
confirmation, with the terms of the floor 
contract recorded in the insurance com­
pany’s accounting records and found
them to be in agreement. _________  __________  _________
19. Obtained documentation for one report­
ing period (for example, monthly or 
quarterly), that the insurance company 
determined that its accounting records 
for floors, tested in procedure 18, agreed 
with or reconciled to the related control 
account; for example, the subsidiary
ledger to the general ledger. _________  __________  _________
20. Obtained the accounting record docu­
menting modifications, if any, to the 
floor agreement. Compared the name of 
the individual who approved the modifi­
cation with a list of individuals autho­
rized to approve modifications and 
found the name of the individual who
approved the modification on the list. _________  __________  _________
21. Compared the terms of the floor agree­
ment recorded in the insurance com­
pany’s accounting records with the 
terms shown in the executed copy of the 
floor agreement and found them to be in
agreement. _________  __________  _________
22. Obtained documentation for one report­
ing period (for example, monthly or 
quarterly), indicating that the insurance 
company physically inventoried the
floor agreements. _________  __________  _________
(continued)
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23. Using the list of authorized traders ob­
tained in procedure 12, compared the 
name of the individual who had custody 
or access to the floor agreement with the 
names of individuals authorized to exe­
cute purchases, sales, or closeouts of 
floor contracts and found that the name 
was not on the list.
24. Compared information regarding the 
floor, such as type of derivative, notional 
amount, and fair value, with the compa­
rable information included in the report 
to the board of directors or appropriate 
committee thereof and found them to be 
in agreement.
25. If the floor should have been included in 
the monitoring analysis separately 
tested in procedure 10 within section 1, 
“All Derivative Types,” compared infor­
mation regarding the floor, such as type 
of derivative, notional amount, and fair 
value, with the comparable information 
in the monitoring analysis and found 
them to be in agreement.
26. Read accounting documentation indi­
cating that the insurance company mon­
itored periodic cash settlements related 
to the floor tested, meaning, the insur­
ance company had controls in place to 
determine that periodic cash settle­
ments, if any, were received.
Effectiveness of Floors Used As Hedges and
in Replication Transactions
27. Read the insurance company’s docu­
mentation of effectiveness and found 
that the insurance company evaluated 
the effectiveness of the floor as a hedge 
or replication in accordance with the 
policies regarding effectiveness.
28. If the floor was no longer effective as a 
hedge or replication, compared the ac-
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tion taken by the insurance company 
with the action required by the account­
ing policies and procedures and found 
that the action taken was consistent 
with the accounting policy.
Legal Review
29. Read documentation indicating that the 
legal department reviewed the floor 
agreement to assess contract compli­
ance with the DUP and enforceability.
30. Read documentation indicating that the 
legal department updated its assessment 
of agreement enforceability at least an­
nually.
Valuation
31. Obtained the insurance company’s poli­
cies and procedures for valuing floors 
and found that the insurance company 
determined the fair value of the floor in 
accordance with the policy described in 
the insurance company’s procedures for 
the valuation of floors.
32. Read documentation supporting the fair 
value of the floor and found that the fair 
value was either (a) obtained from an in­
dependent source, (b) checked against 
an independent source, or (c) calculated 
internally by an authorized individual.
Description of Exceptions if Any
Procedure Number Description of Exception
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Performed the following procedures on se­
lected forward contracts to test internal con­
trol over forward transactions. Selected five 
percent of each type of forward transaction, 
with the selections distributed throughout 
the year. These are, (1) forward contracts 
entered into to make delivery, (2 ) forward 
contracts entered into to take delivery, (3) 
forward contracts settled by making delivery, 
(4) forward contracts settled by taking deliv­
ery, (5) forward contracts settled by cash. If 
five percent of a given type of transaction ex­
ceeded 40, the number of items selected for 
that type of transaction was limited to 40. If 
five percent of a type of transaction resulted 
in less than four items, selected four or fewer 
items that represented all of the transactions 
of that type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to enter 
into forward contracts.
2. For each forward selected for testing, 
read management’s documentation de­
scribing the intended use of the forward 
and performed the following procedures, 
as applicable.
For forward contracts used as a hedge—
3. Determined that the documentation de­
scribes the following:
a. The risk hedged
b. How the hedge was consistent with 
the overall risk management strategy
c. How the forward was expected to be 
effective in offsetting the exposure
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d. The approach in assessing the effec­
tiveness of the hedge ------------  -------------  ----------
4. Determined that the following items 
were documented:
a. The purpose(s) of the forward as a
hedge _________  __________  ________
b. The terms of the forward, the name of 
the counterparty, and the counter­
party exposure amount _________  __________  ________
c. The assets or liabilities (or portion
thereof) that the forward hedged _________  __________  ________
d. The specific forward contract used in
the hedge _________  __________  ________
e. Evidence that the forward continued
to be an effective hedge _________  __________  ________
f. Evidence that the forward was consis­
tent with the insurance company’s pa­
rameters, as specified in the DUP or 
applicable company policies and pro­
cedures, for entering into hedge trans­
actions; for example, the notional
amount or underlying _________  __________  ________
If the forward was an exact offset of an out­
standing forward—
5. Read documentation indicating that the 
forward offset an outstanding forward 
previously purchased or sold by the in­
surance company and that the forward 
was an exact offset of the market risk of
the forward being offset. _________  __________  ________
For forwards used in a replication transac­
tion—
6. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated _________  __________  ________
Findings
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b. How the replication was consistent 
with the overall management invest­
ment strategy
c. How the forward was expected to be 
effective in replicating the investment 
characteristic of the replicated invest­
ment
d. The approach for assessing the effec­
tiveness of the replication transaction
7. Determined that the following items 
were documented:
a. The instruments used in the replica­
tion and the investment type and 
characteristics replicated
b. The terms of the forward contract, the 
name of the counterparty, and the 
counterparty exposure amount
For all selected forwards, including those 
that are a part of the replication transac­
tion—
8. Obtained a list of individuals, approved 
by the board of directors or a committee 
thereof who had the authority to autho­
rize forward transactions. Compared the 
name of the individual who authorized 
the forward transaction with the names 
on the list and found the name of the in­
dividual on the list.
9. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s 
policy regarding the requirement for the 
board of directors or a committee 
thereof to authorize the specific transac­
tion tested; for example, a transaction in 
which the notional amount exceeded a 
limit requiring additional approval. If 
the board of directors or a committee 
thereof was required to approve the
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transaction, read minutes of the board of 
directors or a committee thereof or 
other appropriate support and found ev­
idence of approval of the transaction
tested. _________  __________  _________
10. Obtained a list of qualified and nonquali­
fied counterparties, approved by the 
board of directors or a committee 
thereof. Compared the name of the coun­
terparty involved in the forward transac­
tion with names on the list and found the 
name of the counterparty on the respec­
tive qualified or nonqualified list. _________  __________  _________
11. Determined that the counterparty was 
listed as qualified or nonqualified in the 
analysis used for monitoring the insur­
ance company’s limitations on counter­
party exposure consistent with the 
classification in the listing obtained in
procedure 10. _________  __________  _________
12. Obtained a list of individuals authorized 
by the board of directors or committee 
thereof to trade forward contracts. Com­
pared the name of the individual who exe­
cuted the purchase or sale of the forward 
with the names on the list and found the
name of the individual on the list. _________  __________  _________
13. Obtained a list of individuals authorized 
to approve settlements or payments re­
lated to forward contracts. For the pur­
chase and any transaction subsequent to 
purchase, compared the name of the in­
dividual who approved any payment or 
settlement of funds in connection with 
the forward contract with the names on 
the list and found the name of the indi­
vidual on the list. _________  __________  _________
14. Compared the name of the individual 
who approved any settlement or pay­
ment relating to the forward with the 
name of the individual who approved en-
(continued)
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tering into the contract and found that 
the names were different.
15. Compared the name of the individual 
who received cash or other considera­
tion in connection with the forward with 
the name of the individual who entered 
into the contract and found that the 
names of the individuals were different.
16. Obtained the deal ticket and confirma­
tion for the purchase or sale of the for­
ward contract and found that the 
purchase or sale was confirmed by the 
counterparty.
17. Compared the name of the individual 
who received the deal ticket and confir­
mation with the names on a list of indi­
viduals authorized to trade forwards and 
found that the name was not on the list.
18. Compared the terms of the forward con­
tract, as stated on the deal ticket and 
confirmation, with the terms of the for­
ward contract recorded in the insurance 
company’s accounting records and 
found them to be in agreement.
19. Obtained documentation for one report­
ing period, (for example, monthly or 
quarterly), that the insurance company 
determined that its accounting records 
for forwards, tested in procedure 18, 
agreed with or reconciled to the related 
control account, (for example, the sub­
sidiary ledger to the general ledger).
20. Obtained the accounting record docu­
menting modifications, if any, to the for­
ward contract. Compared the name of 
the individual who approved the modifi­
cation with a list of individuals autho­
rized to approve modifications and 
found the name of the individual who 
approved the modification on the list.
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21. For one reporting period, (for example, 
monthly or quarterly), obtained the in­
surance company’s documentation of 
the existence of the forward contract 
and found that the insurance company 
either (a ) obtained a statement from the 
custodian confirming the existence of 
the forward contract, (b) physically in­
ventoried the forward contract, or (c) 
obtained a statement from the counter­
party acknowledging the existence of
the forward contract _________  __________  _________
22. Using the list of authorized traders ob­
tained in procedure 12, compared the 
name of the individual who had custody 
or access to the forward with the names 
of individuals authorized to execute pur­
chases and sales of forwards and found
that the name was not on the list. _________  __________  _________
23. Compared information regarding the 
forward, such as type of derivative, no­
tional amount, and fair value, with the 
comparable information included in the 
report to the board of directors or appro­
priate committee thereof and found
them to be in agreement. _________  __________  _________
24. If the forward should have been included 
in the monitoring analysis separately 
tested in step 10 within section 1, “All 
Derivative Types,” compared informa­
tion regarding the forward, such as type 
of derivative, notional amount, and fair 
value, with the comparable information 
in the monitoring analysis and found
them to be in agreement. _________  __________  _________
Effectiveness of Forward Contracts Used As
Hedges and in Replication Transactions
25. Read the insurance company’s docu­
mentation of effectiveness and found 
that the insurance company evaluated 
the effectiveness of the forward as a
(continued)
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hedge or replication in accordance with 
the policies regarding effectiveness.
26. If the forward was no longer effective as 
a hedge or replication, compared the ac­
tion taken by the insurance company 
with the action required by the account­
ing policies and procedures and found 
that the action taken was consistent 
with the accounting policy.
Legal Review
27. Read documentation indicating that the 
legal department reviewed the forward 
contract to assess contract compliance 
with the DUP and enforceability.
28. Read documentation indicating that the 
legal department updated its assessment 
of contract enforceability at least annu­
ally.
Valuation
29. Obtained the insurance company’s poli­
cies and procedures for valuing forwards 
and found that the insurance company 
determined the fair value of the forward 
in accordance with the policy described 
in the insurance company’s procedures 
for valuation of forwards.
30. Read documentation supporting the fair 
value of the forward contract and found 
that the fair value was either (a ) ob­
tained from an independent source, (b) 
checked against an independent source, 
or (c) calculated internally by an autho­
rized individual.
Description of Exceptions if Any
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Performed the following procedures on se­
lected futures contracts to test internal con­
trol over futures transactions. Selected five 
percent of each type of futures transactions 
with the selections distributed throughout 
the year. These are purchases, sales, and 
cash settlements (closeouts of a position). If 
five percent of a given type of transaction 
exceeded 40, the number of items selected 
for that type of transaction was limited to 
40. If five percent of a type of transaction re­
sulted in less than four items, selected four 
or fewer items that represented all of the 
transactions of that type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to trade
futures. _________  __________  _________
2. For each futures transaction selected for 
testing, read management’s documenta­
tion describing the intended use of the 
futures and performed the following pro­
cedures, as applicable. _________  __________  _________
For futures used as a hedge—
3. Determined that the documentation de­
scribes the following:
a. The risk hedged _________  __________  _________
b. How the hedge was consistent with
the overall risk management strategy _________  __________  _________
c. How the futures position was expected 
to be effective in offsetting the expo­
sure ------------  -------------  ------------
d. The approach in assessing the effec­
tiveness of the hedge ------------  -------------  ------------
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4. Determined that the following items 
were documented:
a. The purpose(s) of the futures as a
hedge ------------  -------------  ---------
b. The terms of the futures transaction 
and the name of the exchange and
firm(s) handling the trade ------------  -------------  ---------
c. The assets or liabilities (or portion 
thereof) that the futures transaction
hedged ------------  -------------  ---------
d. Evidence that the futures contract
continued to be an effective hedge _________  __________  _______
e. Evidence that the futures position was 
consistent with the insurance com­
pany’s parameters, as specified in the 
DUP or applicable company policies 
and procedures for futures transac­
tions; for example, the notional
amount or underlying _________  __________  _______
For futures transactions that were an exact 
offset of an outstanding futures transac­
tion—
5. Read documentation indicating that the 
futures transaction offset an outstanding 
futures position previously purchased or 
sold by the insurer and that the futures 
transaction was an exact offset of the 
market risk of the futures position being
offset. _________  __________  _______
For futures used in a replication transac­
tion—
6. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated _________  __________  _______
b. How the replication was consistent 
with the overall management invest­
ment strategy _________  __________  _______
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c. How the futures position was expected 
to be effective in replicating the in­
vestment characteristics of the repli­
cated investment
d. The approach in assessing the effec­
tiveness of the replication transaction
7. Determined that the following items 
were documented:
a. The instruments used in the replica­
tion and the investment type and 
characteristics replicated
b. The terms of the futures transaction 
and the name of the exchange and the 
firm(s) handling the trade
c. The specific futures contract used in 
the replication
For all selected futures including those that
are a part of the replication transaction—
8. Obtained a list of individuals, approved 
by the board of directors or a committee 
thereof, who had the authority to autho­
rize futures trades. Compared the name 
of the individual who authorized the fu­
tures transaction with the names on the 
list and found the name of the individual 
on the list.
9. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s pol­
icy regarding the requirement for the 
board of directors or a committee thereof 
to authorize the specific transaction 
tested; for example, a transaction in 
which the notional amount exceeded a 
limit requiring additional approval. If the 
board of directors or a committee thereof 
was required to approve the transaction, 
read minutes of the board of directors or 
a committee thereof or other appropriate
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support and found evidence of approval 
of the transaction tested.
10. Obtained a list of individuals authorized 
by the board of directors or committee 
thereof to trade futures contracts. Com­
pared the name of the individual who 
executed the purchase or sale of the fu­
tures contract with the names on the list 
and found the name of the individual on 
the list.
11. Obtained a list of individuals authorized 
to approve settlements or disbursements 
related to futures transactions. For pur­
chases and transactions subsequent to 
purchase or sale of the futures contract, 
compared the name of the individual 
who approved any settlement of funds 
relating to the futures with the names on 
the list and found the name of the indi­
vidual on the list.
12. Compared the name of the individual 
who approved any payment relating to 
the futures with the name of the individ­
ual who approved entering into the con­
tract and found that the names were 
different.
13. Compared the name of the individual 
who received cash or other considera­
tion in connection with the futures with 
the name of the individual who entered 
into the contract and found that the 
names of the individuals were different.
14. Obtained the deal ticket and confirma­
tion for the purchase, expiration, or sale 
of the futures contracts and found that 
the purchase, sale, or expiration of the 
futures contract was confirmed by the 
deal ticket and confirmation.
15. Compared the terms of the futures 
transaction, as stated on the deal ticket 
and confirmation, with the terms of the
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transaction recorded in the insurance 
company’s accounting records and
found them to be in agreement. _________  __________  _________
16. Obtained documentation for one report­
ing period, (for example, monthly or 
quarterly), that the insurance company 
determined that its accounting records 
for futures, tested in procedure 15, 
agreed with or reconciled to the related 
control account, (for example, the sub­
sidiary ledger to the general ledger). _________  __________  _________
17. For one reporting period, (for example, 
monthly or quarterly), obtained the in­
surance company’s documentation of the 
existence of the futures contracts and 
found that the insurance company ob­
tained statements from the futures coun- 
terparty(ies) or broker(s) confirming the 
futures transactions and positions.
18. Compared information regarding the fu­
tures contract, such as type of derivative, 
notional amount, and fair value, with the 
comparable information included in the 
report to the board of directors or appro­
priate committee thereof and found 
them to be in agreement.
19. If the futures position should have been 
included in the monitoring analysis sepa­
rately tested in procedure 10 within sec­
tion 1, “ All Derivative Types,” compared 
information regarding the futures con­
tract, such as type of derivative, notional 
amount, and fair value, with the compa­
rable information in the monitoring 
analysis and found them to be in agree­
ment. _________  __________  _________
Effectiveness of Futures Used As Hedges
and in Replication Transactions
20. Read the insurance company’s docu­
mentation of effectiveness and found
that the insurance company evaluated (continued)
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the effectiveness of the futures position 
as a hedge or replication in accordance 
with the policies regarding effectiveness.
21. If the futures position was no longer ef­
fective as a hedge or replication, com­
pared the action taken by the insurance 
company with the action required by 
the company policies and procedures 
and found that the action taken was con­
sistent with the accounting policy.
Valuation
22. Obtained the insurance company’s poli­
cies and procedures for valuing positions 
and found that the insurance company 
determined the valuation of the futures 
contract in accordance with the policy 
described in the insurance company’s 
procedures for valuation of futures.
23. Read documentation supporting the 
market price of the futures contract and 
found that the market price was ob­
tained from an independent source.
Description of Exceptions if Any
Procedure Number Description of Exception
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Section 7— Option Contracts
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Procedures Exception Exception N/A
Performed the following procedures on se­
lected option contracts to test internal con­
trol over option transactions. Selected five 
percent of each type of option transaction 
(that is, purchases, sales, expirations, and 
exercises), with the selections distributed 
throughout the year. If five percent of a given 
type of transaction exceeded 40, the number 
of items selected for that type of transaction 
was limited to 40. If five percent of a type of 
transaction resulted in less than four items, 
selected four or fewer items that represented 
all of the transactions of that type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to trade 
or enter into option contracts.
2. For each option selected for testing, read 
management’s documentation describ­
ing the intended use of the option and 
performed the following procedures, as 
applicable.
For options used as a hedge—
3. Determined that the documentation de­
scribed the following:
a. The risk hedged
b. How the hedge was consistent with 
the overall risk management strategy
c. How the option was expected to be ef­
fective in offsetting the exposure
d. The approach in assessing the effec­
tiveness of the hedge
(continued)
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4. Determined that the following items 
were documented:
a. The purpose(s) of the option as a 
hedge
b. For over-the-counter (O TC) options, 
the terms of the option, the name of 
the counterparty, and the counter­
party exposure amount
c. For exchange-traded options, the term 
of the option, the name of the ex­
change, and the name of the firm(s) 
handling the trade
d. The assets or liabilities (or portion 
thereof) that the option hedged
e. For OTC and exchange-traded op­
tions, the specific option used in the 
hedge
f. Evidence that the option continued to 
be an effective hedge
g. Evidence that the option was consis­
tent with the insurance company’s pa­
rameters, as specified in the DUP or 
applicable company policies and pro­
cedures, for entering into hedge trans­
actions; for example, the notional 
amount, or underlying
If the option transaction was (a) for income 
generation and was for the sale of a call op­
tion on securities or (b) an exact offset to an 
outstanding option—
5. Read the documentation supporting the 
transaction which indicated that the in­
surance company was holding or could 
immediately acquire through the exer­
cise of options, warrants, or conversion 
rights already owned, the underlying se­
curities during the entire period the op­
tion was outstanding.
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6. Read documentation indicating that the 
option offset an outstanding option pre­
viously purchased or sold by the insur­
ance company and that the option was 
an exact offset to the market risk of the
option being offset. _________  __________  _________
For options used in a replication transac­
tion—
7. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated _________  __________  _________
b. How the replication was consistent 
with the overall management invest­
ment strategy _________  __________  _________
c. How the option was expected to be ef­
fective in replicating the investment 
characteristics of the replicated in­
vestment _________  __________  _________
d. The approach in assessing the effec­
tiveness of the replication transaction ------------  -------------  ------------
8. Determined that the following items 
were documented:
a. The instruments used in the replica­
tion and the investment type and
characteristics replicated ------------  -------------  ------------
b. The specific option used in the repli­
cation ------------  -------------  ------------
c. For OTC options, the terms of the op­
tion, the name of the counterparty, and
the counterparty exposure amount _________  __________  _________
d. For exchange-traded options, the 
name of the exchange and the firm(s)
handling the trade _________  __________  _________
For all selected options, including those that 
are a part of a replication transaction—
(continued)
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9. Obtained a list of individuals, approved 
by the board of directors or a committee 
thereof, who had the authority to autho­
rize option transactions. Compared the 
name of the individual who authorized 
the option transaction with the names 
on the list and found the name of the in­
dividual on the list.
10. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s 
policy regarding the requirement for the 
board of directors or a committee 
thereof to authorize the specific transac­
tion tested; for example, a transaction in 
which the notional amount exceeded a 
limit requiring additional approval. If 
the board of directors or a committee 
thereof was required to approve the 
transaction, read minutes of the board of 
directors or a committee thereof or 
other appropriate support and found ev­
idence of approval of the transaction 
tested.
11. Obtained a list of qualified and non­
qualified counterparties, approved by 
the board of directors or a committee 
thereof. Compared the name of the 
counterparty involved in the option 
transaction with names on the list and 
found the name of the counterparty on 
the respective qualified or nonqualified 
list.
12. For OTC options, determined that the 
counterparty was listed as qualified or 
nonqualified in the analysis used for 
monitoring the insurance company’s 
limitations on counterparty exposure 
consistent with the classification in the 
listing obtained in procedure 11.
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13 Obtained a list of individuals authorized 
by the board of directors or committee 
thereof to trade option contracts. Com­
pared the name of the individual who 
executed the purchase, sale, or exercise 
of the option with the names on the list 
and found the name of the individual on
the list. _________  __________  _________
14. Obtained a list of individuals authorized 
to approve payments relating to options 
contracts. Compared the name of the in­
dividual who approved any payment re­
lating to the option with the names on 
the list and found the name of the indi­
vidual on the list. _________  __________  _________
15. Compared the name of the individual 
who approved any payment relating to 
the option with the name of the individ­
ual who approved entering into the con­
tract and found that the names were
different. _________  __________  _________
16. Compared the name of the individual 
who received cash or other considera­
tion in connection with the option with 
the name of the individual who entered 
into the contract and found that the
names of the individuals were different. _________  __________  _________
17. Obtained the deal ticket and confirma­
tion for the purchase, sale, or exercise of 
the option and found that the purchase, 
sale, or exercise of the option was con­
firmed by the counterparty or firm han­
dling the transaction. _________  __________  _________
18. Compared the name of the individual 
who received the deal ticket and confir­
mation with the names on a list of indi­
viduals authorized to trade options and
found that the name was not on the list. _________  __________  _________
19. Compared the terms of the option con­
tract, as stated on the deal ticket and 
confirmation, with the terms of the op-
(continued)
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tion contract recorded in the insurance 
company’s accounting records and 
found them to be in agreement.
20. Obtained documentation for one report­
ing period, (for example, monthly or 
quarterly), indicating that the insurance 
company determined whether its ac­
counting records for options, tested in 
procedure 19, agreed with or reconciled 
to the related control account, (for ex­
ample, the subsidiary ledger to the gen­
eral ledger).
21. Obtained the accounting record docu­
menting modifications, if any, to the op­
tion transaction. Compared the name of 
the individual who approved the modifi­
cation with a list of individuals autho­
rized to approve modifications and 
found the name of the individual who 
approved the modification on the list.
22. Obtained documentation for one report­
ing period, (for example, monthly or 
quarterly), indicating that the insurance 
company obtained a statement from the 
counterparty confirming the existence 
of the option position.
23. Using the list of authorized traders ob­
tained in procedure 13, compared the 
name of the individual who had custody 
of or access to the option documenta­
tion with the names of individuals au­
thorized to purchase, sell, or exercise 
the option and found that the name was 
not on the list.
24. Compared information regarding the op­
tion, such as type of derivative, notional 
amount, and fair value, with the compa­
rable information included in the report 
to the board of directors or appropriate 
committee thereof and found them to be 
in agreement.
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25. If the option should have been included 
in the monitoring analysis separately 
tested in procedure 10 within section 1,
“All Derivative Types,” compared infor­
mation regarding the option, such as 
type of derivative, notional amount, and 
fair value, with the comparable informa­
tion in the monitoring analysis and
found them to be in agreement. _________  __________  _________
Effectiveness of Options Used As Hedges
and in Replication Transactions
26. Read the insurance company’s docu­
mentation of effectiveness and found 
that the insurance company evaluated 
the effectiveness of the option as a hedge 
or replication in accordance with the
policies regarding effectiveness. _________  __________  _________
27. If the option was no longer effective as a 
hedge or replication, compared the ac­
tion taken by the insurance company 
with the action required by the account­
ing policies and procedures and found 
that the action taken was consistent
with the accounting policy. ------------  -------------  ------------
Legal Review
28. Read documentation indicating that the 
legal department reviewed the option 
agreement to assess contract compli­
ance with the DUP and enforceability. _________  __________  _________
29. Read documentation indicating that the 
legal department updated its assessment 
of legal enforceability of the OTC option
agreement at least annually. _________  __________  _________
Valuation
30. Obtained the insurance company’s poli­
cies and procedures for valuing options 
and found that the insurance company 
determined the fair value of OTC op­
tions and the market price of exchange-  (continued)
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traded options, in accordance with the 
policy described in the insurance com­
pany’s procedures for the valuation of 
options.
31. Read documentation supporting the fair 
value for OTC options and the market 
price of exchange-traded options and 
found that the fair value or market value 
was either (a ) obtained from an inde­
pendent source, (b) checked against an 
independent source, or (c) calculated in­
ternally by an authorized individual.
Description of Exceptions if Any 
Procedure Number Description of Exception
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Procedures Exception Exception N/A
Performed the following procedures on se­
lected swap contracts to test internal con­
trol over swap transactions. Selected five 
percent of each type of swap transaction 
(that is, executions [purchases] and close­
outs [sales]), with the selections distributed 
throughout the year. If five percent of a 
given type of transaction exceeded 40, the 
number of items selected for that type of 
transaction was limited to 40. If five percent 
of a type of transaction resulted in fewer 
than four items, selected four or fewer items 
that represented all the transactions of that 
type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to enter
into swap agreements. _________  __________  _________
2. For each swap agreement selected for 
testing, read management’s documenta­
tion describing the intended use of the 
swap agreement and performed the fol­
lowing procedures, as applicable. ------------  -------------  ------------
For swaps used as a hedge—
3. Determined that the documentation de­
scribes the following:
a. The risk hedged _________  __________  _________
b. How the hedge was consistent with
the overall risk management strategy _________  __________  _________
c. How the swap was expected to be ef­
fective in offsetting the exposure _________  __________  _________
d. The approach in assessing the effec­
tiveness of the hedge _________  __________  _________
(continued)
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4. Determined that the following items 
were documented:
a. The purpose(s) of the swap as a hedge
b. The terms of the swap, the name of 
the counterparty, and the counter­
party exposure amount
c. The assets or liabilities (or portion 
thereof) that the swap hedged
d. Evidence that the swap continued to 
be an effective hedge
e. Evidence that the swap was consistent 
with the insurance company’s para­
meters, as specified in the DUP or ap­
plicable policies and procedures, for 
entering into swap agreements; for ex­
ample, the notional amount or under­
lying
For swaps that were an exact offset of an 
outstanding swap—
5. Read documentation that indicated that 
the swap offset a swap previously pur­
chased or sold, and that the swap was an 
exact offset to the market risk of the 
swap being offset.
For swaps used in a replication transac­
tion—
6. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated
b . How the replication was consistent 
with the overall management invest­
ment strategy
c. How the swap was expected to be ef­
fective in replicating the investment 
characteristic of the replicated invest­
ment
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d. The approach in assessing the effec­
tiveness of the replication transaction ------------  -------------  ------------
7. Determined that the following items 
were documented:
a. The instruments used in the replica­
tion and the investment type and
characteristics replicated _________  __________  _________
b. The terms of the swap, the name of 
the counterparty, and the counter­
party exposure amount _________  __________  _________
For all selected swaps including those that
are a part of a replication transaction—
8. Obtained a list of individuals, approved 
by the board of directors or a committee 
thereof who had the authority to autho­
rize swap transactions. Compared the 
name of the individual who authorized 
the swap transaction with the names on 
the list and found the name of the indi­
vidual on the list. _________  __________  _________
9. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s pol­
icy regarding the requirement for the 
board of directors or a committee thereof 
to authorize the specific transactions 
tested; for example, a transaction in 
which the notional amount exceeded a 
limit requiring additional approval. If the 
board of directors or a committee thereof 
was required to approve the transaction, 
read minutes of the board of directors or 
a committee thereof or other appropriate 
support and found evidence of approval
of the transaction tested. _________  __________  _________
10. Obtained a list of qualified and non­
qualified counterparties, approved by 
the board of directors or a committee 
thereof. Compared the name of the
(continued)
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counterparty involved in the swap agree­
ment with names on the list and found 
the name of the counterparty on the re­
spective qualified or nonqualified list.
11. Determined that the counterparty was 
listed as qualified or nonqualified in the 
analysis used for monitoring the insur­
ance company’s limitations on counter­
party exposure consistent with the 
classification in the listing obtained in 
procedure 10.
12. Obtained a list of individuals authorized 
by the board of directors or committee 
thereof to trade swap contracts. Com­
pared the name of the individual who 
executed the swap with the names on 
the list and found the name of the indi­
vidual on the list.
13. Obtained a list of individuals authorized 
to approve settlements or disbursements 
related to swaps. For purchases and any 
interim settlements or closeouts of the 
swap subsequent to purchase, compared 
the name of the individual who ap­
proved any settlement of funds relating 
to the swap with the names on the list 
and found the name of the individual on 
the list.
14. Compared the name of the individual 
who approved any payment relating to 
the swap with the name of the individual 
who approved entering into the contract 
and found that the names were different.
15. Compared the name of the individual 
who received cash or other considera­
tion in connection with the swap with 
the name of the individual who entered 
into the contract and found that the 
names of the individuals were different.
16. Obtained the deal ticket and confirma­
tion for the purchase, execution, or
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closeout of the swap and found that the 
purchase, execution, or closeout of the 
swap was confirmed by the counter­
party. _________ _______________________
17. Compared the name of the individual 
who received the deal ticket and confir­
mation with the names on a list of indi­
viduals authorized to trade swaps and
found that the name was not on the list. _________  __________  _________
18. Compared the terms of the swap con­
tract, as stated on the deal ticket and 
confirmation, with the terms of the swap 
contract recorded in the insurance com­
pany’s accounting records and found
them to be in agreement. _________  __________  _________
19. Obtained documentation for one report­
ing period, (for example, monthly or 
quarterly), that the insurance company 
determined whether its accounting 
records for swaps, tested in procedure
18, agreed with or reconciled to the re­
lated control account, (for example, the
subsidiary ledger to the general ledger). _________  __________  _________
20. Obtained the accounting record docu­
menting modifications, if any, to the 
swap agreement. Compared the name of 
the individual who approved the modifi­
cation with a list of individuals autho­
rized to approve modifications and 
found the name of the individual who
approved the modification on the list. _________  __________  _________
21. Compared the terms of the swap agree­
ment recorded in the insurance com­
pany’s accounting records with the 
terms shown in the executed copy of the 
swap agreement and found them to be in
agreement. _________  __________  _________
22. Using the list of authorized traders ob­
tained in procedure 12, compared the 
name of the individual who had custody 
or access to the swap agreement with
(continued)
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the names of individuals authorized to 
execute swap agreements and found that 
the name was not on the list.
23. Compared information regarding the 
swap, such as type of derivative, no­
tional amount, and fair value, with the 
comparable information included in the 
report to the board of directors or appro­
priate committee thereof and found 
them to be in agreement.
24. If the swap should have been included in 
the monitoring analysis separately 
tested in procedure 10 within section 1, 
“All Derivative Types,” compared infor­
mation regarding the swap, such as type 
of derivative, notional amount, and fair 
value, with the comparable information 
in the monitoring analysis and found 
them to be in agreement.
25. Read accounting documentation indi­
cating that the insurance company mon­
itored periodic cash settlements related 
to swap transactions, meaning, the in­
surance company had controls in place 
to determine that periodic cash settle­
ments, if any, were received.
Effectiveness of Swaps Used As Hedges and
in Replication Transactions
26. Read the insurance company’s docu­
mentation of effectiveness and found 
that the insurance company evaluated 
the effectiveness of the swap as a hedge 
or replication in accordance with the 
policies regarding effectiveness.
27. If the swap was no longer effective as a 
hedge or replication, compared the ac­
tion taken by the insurance company 
with the action required by the account­
ing policies and procedures and found 
that the action taken was consistent 
with the accounting policy.
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Legal Review
28. Read documentation indicating that the 
legal department reviewed the swap 
agreement to assess contract compli­
ance with the DUP and enforceability. _________  __________  _______
29. Read documentation indicating that the 
legal department updated its assessment 
of the enforceability of the swap agree­
ment at least annually. _________  __________  _______
Valuation
30. Obtained the insurance company’s poli­
cies and procedures for valuing swaps 
and found that the insurance company 
determined the fair value of the swap in 
accordance with the policy described in 
the insurance company’s procedures for
valuation of swaps. _________  __________  _______
31. Read documentation supporting the fair 
value of the swap and found that the fair 
value was either (a ) obtained from an in­
dependent source, (b) checked against 
an independent source, or (c) calculated
internally by an authorized individual. _________  __________  _______
Description of Exceptions if Any
Procedure Number Description of Exception
(continued)
79
Section 9— Swaption Contracts
Findings
Procedures Exception Exception N/A
Performed the following procedures on se­
lected swaption contracts to test internal 
control over swaption transactions. Selected 
five percent of each type of swaption trans­
action with the selections distributed 
throughout the year. These are executions 
(purchases) and closeouts (sales). If five 
percent of a given type of transaction ex­
ceeded 40, the number of items selected for 
that type of transaction was limited to 40. If 
five percent of a type of transaction resulted 
in less than four items, selected four or 
fewer items that represented all the transac­
tions of that type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to buy 
or sell swaptions.
2. For each swaption contract selected for 
testing, read management’s documenta­
tion describing the intended use of the 
swaption and performed the following 
procedures, as applicable.
For swaptions used as a hedge—
3. Determined that the documentation de­
scribes the following:
a. The risk hedged
b. How the hedge was consistent with 
the overall risk management strategy
c. How the swaption was expected to be 
effective in offsetting the exposure
d. The approach in assessing the effec­
tiveness of the hedge
No
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4. Determined that the following items 
were documented:
a. The purpose(s) of the swaption as a 
hedge
b. The terms of the swaption, the name 
of the counterparty, and the counter­
party exposure amount
e. The assets or liabilities (or portion 
thereof) that the swaption hedged
d. Evidence that the swaption continued 
to be an effective hedge
e. Evidence that the swaption was con­
sistent with the insurance company’s 
parameters, as specified in the DUP or 
applicable policies and procedures, for 
entering into swaption agreements; 
for example, the notional amount or 
underlying
For swaptions that were an exact offset of an 
outstanding swaption—
5. Read documentation indicating that the 
swaption offset an outstanding swaption 
and that the swaption was an exact off­
set of the market risk of the swaption 
being offset.
For swaptions used in a replication transac­
tion—
6. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated
b. How the replication was consistent 
with the overall management invest­
ment strategy
c. How the swaption was expected to be 
effective in replicating the investment
(continued)
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characteristic of the replicated invest­
ment
d. The approach in assessing the effec­
tiveness of the replication transaction
7. Determined that the following items 
were documented:
a. The instruments used in the replica­
tion and the investment type and 
characteristics replicated
b. The terms of the swaption, the name 
of the counterparty, and the counter­
party exposure amount
For all selected swaptions including those
that are a part of a replication transaction—
8. Obtained a list of individuals, approved 
by the board of directors or a committee 
thereof, who had the authority to autho­
rize swaptions. Compared the name of 
the individual who authorized the swap­
tion transaction with the names on the 
list and found the name of the individual 
on the list.
9. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s 
policy regarding the requirement for the 
board of directors or a committee 
thereof to authorize the specific transac­
tions tested; for example, a transaction 
in which the notional amount exceeded 
a limit requiring additional approval. If 
the board of directors or a committee 
thereof was required to approve the 
transaction, read minutes of the board of 
directors or a committee thereof or 
other appropriate support and found ev­
idence of approval of the transaction 
tested.
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10. Obtained a list of qualified and nonquali­
fied counterparties, approved by the 
board of directors or a committee 
thereof. Compared the name of the coun­
terparty involved in the swaption trans­
action with names on the list and found 
the name of the counterparty on the re­
spective qualified or nonqualified list. _________  __________  _________
11. Determined that the counterparty was 
listed as qualified or nonqualified in the 
analysis used for monitoring the insur­
ance company’s limitations on counter­
party exposure consistent with the 
classification in the listing obtained in
procedure 10. _________  __________  _________
12. Obtained a list of individuals authorized 
by the board of directors or committee 
thereof to trade swaption contracts.
Compared the name of the individual 
who executed the swaption with the 
names on the list and found the name of
the individual on the list. _________  __________  _________
13. Obtained a list of individuals authorized 
to approve settlements or disbursements 
related to swaption agreements. Com­
pared the name of the individual who ap­
proved settlements and disbursements 
relating to the swaption with the names
on the list and found the name on the list. ------------  -------------  ------------
14. Compared the name of the individual 
who approved any payment relating to 
the swaption with the name of the indi­
vidual who approved entering into the 
contract and found that the names were
different. _________  __________  _________
15. Compared the name of the individual 
who received cash or other consideration 
in connection with the swaption with the 
name of the individual who entered into 
the contract and found that the names of
the individuals were different. _________  __________  _________
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16. Obtained the deal ticket and confirma­
tion for the purchase, sale, modification, 
or closeout of the swaption and found 
that the purchase, sale, modification, or 
closeout was confirmed by the counter­
party.
17. Compared the name of the individual 
who received the deal ticket and confir­
mation with the names on a list of indi­
viduals authorized to trade swaptions and 
found that the name was not on the list.
18. Compared the terms of the swaption 
contract, as stated on the deal ticket and 
confirmation, with the terms of the 
swaption contract recorded in the insur­
ance company’s accounting records and 
found them to be in agreement.
19. Obtained documentation for one report­
ing period, (for example, monthly or 
quarterly), that the insurance company 
determined whether its accounting 
records for swaptions, tested in proce­
dure 18, agreed with or reconciled to the 
related control account, (for example, 
the subsidiary ledger to the general 
ledger).
20. Obtained the accounting record docu­
menting modifications, if any, to the 
swaption agreement. Compared the 
name of the individual who approved the 
modification with a list of individuals au­
thorized to approve modifications and 
found the name of the individual who ap­
proved the modification on the list.
21. Compared the terms of the swaption 
agreement recorded in the insurance 
company’s accounting records with the 
terms shown in the executed copy of the 
swaption agreement and found them to 
be in agreement.
84
Findings
Procedures Exception Exception N/A
22. Using the list of authorized traders ob­
tained in procedure 12, compared the 
name of the individual who had custody 
or access to the swaption agreement 
with the names of individuals authorized 
to execute swaption agreements and
found that the name was not on the list. ------------  -------------  ------------
23. Compared information regarding the 
swaption, such as type of derivative, no­
tional amount, and fair value, with the 
comparable information included in the 
report to the board of directors or appro­
priate committee thereof and found
them to be in agreement. ------------  -------------  ------------
24. If the swaption should have been in­
cluded in the monitoring analysis sepa­
rately tested in procedure 10 within 
section 1, “ All Derivative Types,” com­
pared information regarding the swap­
tion, such as type of derivative, 
notional amount, and fair value, with 
the comparable information in the 
monitoring analysis and found them to
be in agreement. _________  __________  _________
Effectiveness of Swaptions Used As Hedges
and in Replication Transactions
25. Read the insurance company’s docu­
mentation of effectiveness and found 
that the insurance company evaluated 
the effectiveness of the swaption as a 
hedge or replication in accordance with
the policies regarding effectiveness. _________  __________  _________
26. If the swaption was no longer effective as 
a hedge or replication, compared the ac­
tion taken by the insurance company 
with the action required by the account­
ing policies and procedures and found 
that the action taken was consistent
with the accounting policy. _________  __________  _________
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Legal Review
27. Read documentation indicating that the 
legal department reviewed the swaption 
agreement to assess contract compli­
ance with the DUP and enforceability.
28. Read documentation indicating that the 
legal department updated its assessment 
of the enforceability of the swaption 
agreement at least annually.
Valuation
29. Obtained the insurance company’s poli­
cies and procedures for valuing swap­
tions and found that the insurance 
company determined the fair value of 
the swaption in accordance with the pol­
icy described in the insurance com­
pany’s procedures for valuation of 
swaptions.
30. Read documentation supporting the fair 
value of the swaption and found that the 
fair value was either (a)  obtained from 
an independent source, (b ) checked 
against an independent source, or (c ) 
calculated internally by an authorized 
individual.
Description of Exceptions if Any
Procedure Number Description of Exception
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Section 10— Warrant Contracts
Findings
Procedures Exception Exception N/A
Performed the following procedures on se­
lected warrant contracts to test internal con­
trol over warrant transactions. Selected five 
percent of each type of warrant transaction 
(that is, purchases, sales, expirations, and 
exercises), with the selections distributed 
throughout the year. If five percent of a given 
type of transaction exceeded 40, the number 
of items selected for that type of transaction 
was limited to 40. If five percent of a type of 
transaction resulted in less than four items, 
selected four or fewer items that represented 
all of the transactions of that type.
Reporting
1. Read the insurance company’s deriva­
tive use plan (DUP) and any amend­
ments thereto and found that the DUP 
permits the insurance company to trade 
or enter into warrant contracts.
2. For each warrant selected for testing, 
read management’s documentation de­
scribing the intended use of the warrant 
and performed the following procedures, 
as applicable.
For warrants used as a hedge—
3. Determined that the documentation de­
scribed the following:
a. The risk hedged
b. How the hedge was consistent with 
the overall risk management strategy
c. How the warrant was expected to be 
effective in offsetting the exposure
d. The approach in assessing the effec­
tiveness of the hedge
4. Determined that the following items 
were documented:
(continued) 
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a. The purpose(s) of the warrant as a 
hedge
b . For exchange-traded warrants, the 
term of the warrant, the name of the 
exchange, and the name of the firm(s) 
handling the trade
c. For over-the-counter (OTC) warrants, 
the terms of the warrant, the name of 
the counterparty, and the counter­
party exposure amount
d. The assets or liabilities (or portion 
thereof) that the warrant hedged
e. Evidence that the warrant continued 
to be an effective hedge
f. Evidence that the warrant was consis­
tent with the insurance company’s pa­
rameters, as specified in the DUP or 
applicable company policies and pro­
cedures for entering into hedge trans­
actions; for example, the notional 
amount or underlying
If the warrant transaction was an exact off­
set of an outstanding warrant—
5. Read documentation indicating that the 
warrant transaction offset an outstanding 
warrant previously purchased or sold by 
the insurance company and that the war­
rant was an exact offset of the market risk 
of the warrant being offset
For warrants used in a replication transac­
tion—
6. Determined that the documentation de­
scribed the following:
a. The investment type and characteris­
tics replicated
b. How the replication was consistent 
with the overall management invest­
ment strategy
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Findings
Procedures Exception Exception N/A
c. How the warrant was expected to be 
effective in replicating the investment 
characteristics of the replicated in­
vestment ________  _________  ________
d. The approach in assessing the effec­
tiveness of the replication transaction ________  _________  ________
7. Determined that the following items 
were documented:
a. The instruments used in the replica­
tion and the investment type and
characteristics replicated ________  _________  ________
b. The specific warrant used in the repli­
cation ________  _________  ________
c. For exchange-traded warrants, the 
name of the exchange and the firm(s)
handling the trade ________  _________  ________
d. For OTC warrants, the terms of the 
warrant, the name of the counter­
party, and the counterparty exposure
amount ________  _________  ________
For all selected warrants including those 
that are part of a replication transaction—
8. Obtained a list of individuals, approved 
by the board of directors or a committee 
thereof who had the authority to autho­
rize warrant transactions. Compared the 
name of the individual who authorized 
the warrant transaction with the names 
on the list and found the name of the in­
dividual on the list. ________  _________  ________
9. Based on the details of the transaction 
identified in procedure 2 and company 
policy, compared the terms of the trans­
action with the insurance company’s 
policy regarding the requirement for the 
board of directors or a committee 
thereof to authorize the specific transac­
tion tested; for example, a transaction in 
which the notional amount exceeded a
(continued)
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limit requiring additional approval. If 
the board of directors or a committee 
thereof was required to approve the 
transaction, read minutes of the board of 
directors or a committee thereof or 
other appropriate support, and found ev­
idence of approval of the transaction 
tested
10. Obtained a list of qualified and nonquali­
fied counterparties, approved by the 
board of directors or a committee 
thereof. Compared the name of the coun­
terparty involved in the warrant transac­
tion with names on the list, and found the 
name of the counterparty on the respec­
tive qualified or nonqualified list.
11. For OTC warrants, determined that the 
counterparty was listed as qualified or 
nonqualified in the analysis used for 
monitoring the insurance company’s 
limitations on counterparty exposure, 
consistent with the classification in the 
listing obtained in procedure 10.
12. Obtained a list of individuals authorized 
by the board of directors or committee 
thereof to trade warrant contracts. Com­
pared the name of the individual who 
executed the purchase, sale, or exercise 
of the warrant with the names on the list 
and found the name of the individual on 
the list.
13. Obtained a list of individuals authorized 
to approve payments related to warrant 
contracts. Compared the name of the in­
dividual who approved any payment re­
lating to the warrant with the names on 
the list, and found the name of the indi­
vidual on the list.
14. Compared the name of the individual 
who approved any payment relating to 
the warrant with the name of the indi­
vidual who approved entering into the
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contract and found that the names were
different. ------------  -------------  ------------
15. Compared the name of the individual 
who received cash or other considera­
tion in connection with the warrant with 
the name of the individual who entered 
into the contract and found that the
names of the individuals were different. _________  __________  _________
16. Obtained the deal ticket and confirma­
tion for the purchase, sale, or exercise of 
an exchange-traded warrant and found 
that the purchase, sale, or exercise was 
confirmed by the firm handling the
transaction. _________  __________  _________
17. Compared the name of the individual 
who received the deal ticket and confir­
mation with the names on a list of indi­
viduals authorized to trade warrants and
found that the name was not on the list. _________  __________  _________
18. Compared the terms of the warrant con­
tract, as stated on the deal ticket and 
confirmation, with the terms of the war­
rant contract recorded in the insurance 
company’s accounting records and
found them to be in agreement. _________  __________  _________
19. Obtained documentation for one report­
ing period, (for example, monthly or 
quarterly), that the insurance company 
determined whether its accounting 
records for warrants, tested in proce­
dure 18, agreed with or reconciled to the 
related control account, (for example, 
the subsidiary ledger to the general
ledger). _________  __________  _________
20. Obtained the accounting record docu­
menting modifications, if any, to the 
warrant transaction. Compared the 
name of the individual who approved 
the modification with a list of individu­
als authorized to approve modifications 
and found the name of the individual
(continued)
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who approved the modification on the 
list.
21. For one reporting period, (for example, 
monthly or quarterly), obtained the in­
surance company’s documentation of 
the existence of the warrant contract 
and found that the insurance company 
either (a)  obtained statements from the 
custodian confirming the existence of 
the warrant contracts or (b) physically 
inventoried the warrant contracts.
22. Using the list of authorized traders ob­
tained in procedure 12, compared the 
name of the individual who had custody 
of or access to the warrant contracts 
with the names of individuals authorized 
to execute purchases, sales, or exercises 
of warrants and found that the name was 
not on the list.
23. Compared information regarding the 
warrant, such as type of derivative, no­
tional amount, and fair value, with the 
comparable information included in the 
report to the board of directors or appro­
priate committee thereof and found 
them to be in agreement.
24. If the warrant position should have been 
included in the monitoring analysis sep­
arately tested in procedure 10 of section 
1, “All Derivative Types,” compared in­
formation regarding the warrant, such as 
type of derivative, notional amount, and 
fair value, with the comparable informa­
tion in the monitoring analysis and 
found them to be in agreement.
Effectiveness of Warrants Used As Hedges
and in Replication Transactions
25. Read the insurance company’s docu­
mentation of effectiveness and found 
that the insurance company evaluated 
the effectiveness of the warrant as a
No
Procedures
Findings
No
Exception Exception N/A
hedge or replication in accordance with 
the policies regarding effectiveness.
26. If the warrant was no longer effective as 
a hedge or replication, compared the ac­
tion taken by the insurance company 
with the action required by the account­
ing policies and procedures and found 
that the action taken was consistent 
with the accounting policy.
Legal Review
27. Read documentation indicating that the 
legal department reviewed a nonex­
change traded warrant agreement to as­
sess contract compliance with the DUP 
and enforceability.
28. Read documentation indicating that the 
legal department updated its assessment 
of enforceability of the nonexchange 
traded warrant agreement at least annu­
ally.
Valuation
29. Obtained the insurance company’s poli­
cies and procedures for valuing warrants 
and found that the insurance company 
determined the fair value of the warrant 
in accordance with the policy described 
in the insurance company’s procedures 
for the valuation of warrants
30. Read documentation supporting the fair 
value of warrants and found that the fair 
value was either (a ) obtained from an in­
dependent source, (b) checked against 
an independent source, or (c) calculated 
internally by an authorized individual.
Description of Exceptions if Any
Procedure Number Description of Exception
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APPENDIX C
Illustrative Management 
Representation Letter
[Responsible Party’s Letterhead]
[Date]
[CPA Firm’s Name and Address]
In connection with your engagement to apply the agreed-upon 
procedures enumerated in the American Institute of Certified 
Public Accountants’ Statement of Position 01-03, Performing 
Agreed-Upon Procedures Engagements that Address Internal 
Control Over Derivative Transactions as Required by the New  
York State Insurance Law, which were agreed to by management 
of ABC Insurance Company, solely to assist us in complying with 
the requirements of Section 1410 (b)(5) of the New York State In­
surance Law, as amended (the Law), which addresses the assess­
ment of internal control over derivative transactions as defined 
in Section 1401 (a) of the Law and Section 178.6 of Regulation 
No. 163 during the year ended December 31, 20XX, we confirm, 
to the best of our knowledge and belief, the following representa­
tions made to you during your engagement:
1. We are responsible for establishing and maintaining effec­
tive internal control over derivative transactions in accor­
dance with the Law.
2. During the year ended December 31, 20XX, the internal 
control over derivative transactions was functioning in ac­
cordance with the policies and procedures set forth in the 
Company’s derivative use plan (DUP) and related account­
ing policies and procedures. There have been no errors or 
fraud that would indicate a weakness in the internal control 
over derivative transactions.
3. We have disclosed to you all significant deficiencies in the 
design or operation of the internal control over derivative 
transactions that would adversely affect the Company’s abil­
ity to function in accordance with the Company’s DUP.
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4. There have been no communications from regulatory agen­
cies, internal auditors, or other practitioners or consultants 
relating to the internal control over derivative transactions, 
including communications received between December 31, 
20XX and the date of this letter.
5. We have made available to you all information that we be­
lieve is relevant to the internal control over derivative trans­
actions.
6. We have responded fully to all inquiries made to us by you 
during the engagement.
To the best of our knowledge and belief, no events have occurred 
subsequent to December 31, 20XX and through the date of this 
letter that would require adjustment to or modification of the 
findings of the agreed-upon procedures.
[Signature]
[Title]
[Signature]
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